168 results on '"Hauser, Stephen"'
Search Results
2. What ethics integration looks like in neuroscience research.
- Author
-
Hauser SL
- Subjects
- Humans, Biomedical Research ethics, Neurosciences ethics
- Published
- 2014
- Full Text
- View/download PDF
3. Big neuroscience.
- Author
-
Hauser SL and Johnston SC
- Subjects
- Human Genome Project, Humans, United States, Brain Mapping, Neurosciences
- Published
- 2013
- Full Text
- View/download PDF
4. Research trainees in the clinical neurosciences: still a shallow pool.
- Author
-
Hauser SL and Johnston SC
- Subjects
- Biomedical Research methods, Humans, National Institutes of Health (U.S.), Training Support, United States, Biomedical Research education, Neurosciences education
- Published
- 2009
- Full Text
- View/download PDF
5. Comparative effectiveness research in the neurosciences.
- Author
-
Johnston SC and Hauser SL
- Subjects
- Biomedical Research methods, Clinical Trials as Topic economics, Clinical Trials as Topic methods, Clinical Trials as Topic statistics & numerical data, National Institute of Neurological Disorders and Stroke (U.S.), Research Support as Topic, United States, Biomedical Research economics, Health Care Costs trends, Neurosciences economics, Neurosciences trends
- Published
- 2009
- Full Text
- View/download PDF
6. Transformative research.
- Author
-
Johnston SC and Hauser SL
- Subjects
- Biomedical Research trends, Neurology trends, Neurosciences trends, Research trends
- Published
- 2008
- Full Text
- View/download PDF
7. A status report on neuroscience research, without grade inflation.
- Author
-
Johnston SC and Hauser SL
- Subjects
- Animals, Biomedical Research economics, Biomedical Research ethics, Drug Design, Drug Industry economics, Drug Industry ethics, Financing, Government standards, Foundations economics, Foundations ethics, Foundations trends, Humans, Nervous System Diseases etiology, Nervous System Diseases prevention & control, Neurosciences economics, Neurosciences ethics, Public Policy, Research economics, Research trends, Research Support as Topic standards, Biomedical Research trends, Drug Industry trends, Financing, Government trends, Nervous System Diseases drug therapy, Neurosciences trends, Research Support as Topic trends
- Published
- 2006
- Full Text
- View/download PDF
8. Transcobalamin receptor antibodies in autoimmune vitamin B12 central deficiency
- Author
-
Pluvinage, John V, Ngo, Thomas, Fouassier, Camille, McDonagh, Maura, Holmes, Brandon B, Bartley, Christopher M, Kondapavulur, Sravani, Hurabielle, Charlotte, Bodansky, Aaron, Pai, Vincent, Hinman, Sam, Aslanpour, Ava, Alvarenga, Bonny D, Zorn, Kelsey C, Zamecnik, Colin, McCann, Adrian, Asencor, Andoni I, Huynh, Trung, Browne, Weston, Tubati, Asritha, Haney, Michael S, Douglas, Vanja C, Louine, Martineau, Cree, Bruce AC, Hauser, Stephen L, Seeley, William, Baranzini, Sergio E, Wells, James A, Spudich, Serena, Farhadian, Shelli, Ramachandran, Prashanth S, Gillum, Leslie, Hales, Chadwick M, Zikherman, Julie, Anderson, Mark S, Yazdany, Jinoos, Smith, Bryan, Nath, Avindra, Suh, Gina, Flanagan, Eoin P, Green, Ari J, Green, Ralph, Gelfand, Jeffrey M, DeRisi, Joseph L, Pleasure, Samuel J, and Wilson, Michael R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Women's Health ,Autoimmune Disease ,Brain Disorders ,Dietary Supplements ,Nutrition ,Clinical Research ,Minority Health ,Neurosciences ,Biotechnology ,2.1 Biological and endogenous factors ,Neurological ,Humans ,Vitamin B 12 Deficiency ,Vitamin B 12 ,Autoantibodies ,Female ,Receptors ,Cell Surface ,Antigens ,CD ,Middle Aged ,Autoimmune Diseases ,Blood-Brain Barrier ,Male ,Biological Sciences ,Medical and Health Sciences ,Medical biotechnology ,Biomedical engineering - Abstract
Vitamin B12 is critical for hematopoiesis and myelination. Deficiency can cause neurologic deficits including loss of coordination and cognitive decline. However, diagnosis relies on measurement of vitamin B12 in the blood, which may not accurately reflect the concentration in the brain. Using programmable phage display, we identified an autoantibody targeting the transcobalamin receptor (CD320) in a patient with progressive tremor, ataxia, and scanning speech. Anti-CD320 impaired cellular uptake of cobalamin (B12) in vitro by depleting its target from the cell surface. Despite a normal serum concentration, B12 was nearly undetectable in her cerebrospinal fluid (CSF). Immunosuppressive treatment and high-dose systemic B12 supplementation were associated with increased B12 in the CSF and clinical improvement. Optofluidic screening enabled isolation of a patient-derived monoclonal antibody that impaired B12 transport across an in vitro model of the blood-brain barrier (BBB). Autoantibodies targeting the same epitope of CD320 were identified in seven other patients with neurologic deficits of unknown etiology, 6% of healthy controls, and 21.4% of a cohort of patients with neuropsychiatric lupus. In 132 paired serum and CSF samples, detection of anti-CD320 in the blood predicted B12 deficiency in the brain. However, these individuals did not display any hematologic signs of B12 deficiency despite systemic CD320 impairment. Using a genome-wide CRISPR screen, we found that the low-density lipoprotein receptor serves as an alternative B12 uptake pathway in hematopoietic cells. These findings dissect the tissue specificity of B12 transport and elucidate an autoimmune neurologic condition that may be amenable to immunomodulatory treatment and nutritional supplementation.
- Published
- 2024
9. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
- Author
-
Bar-Or, Amit, Thanei, Gian-Andrea, Harp, Christopher, Bernasconi, Corrado, Bonati, Ulrike, Cross, Anne H, Fischer, Saloumeh, Gaetano, Laura, Hauser, Stephen L, Hendricks, Robert, Kappos, Ludwig, Kuhle, Jens, Leppert, David, Model, Fabian, Sauter, Annette, Koendgen, Harold, Jia, Xiaoming, and Herman, Ann E
- Subjects
Intermediate Filaments ,Humans ,Multiple Sclerosis ,Multiple Sclerosis ,Chronic Progressive ,Multiple Sclerosis ,Relapsing-Remitting ,Acute Disease ,Disease Progression ,Recurrence ,Biomarker ,Disease progression ,Multiple sclerosis ,NfL ,Ocrelizumab ,Brain Disorders ,Neurodegenerative ,Autoimmune Disease ,Prevention ,Clinical Research ,Clinical Trials and Supportive Activities ,Neurosciences ,Aetiology ,2.1 Biological and endogenous factors ,Neurological ,Clinical Sciences ,Public Health and Health Services - Abstract
BackgroundNeurofilament light chain (NfL), a neuronal cytoskeletal protein that is released upon neuroaxonal injury, is associated with multiple sclerosis (MS) relapsing activity and has demonstrated some prognostic ability for future relapse-related disease progression, yet its value in assessing non-relapsing disease progression remains unclear.MethodsWe examined baseline and longitudinal blood NfL levels in 1421 persons with relapsing MS (RMS) and 596 persons with primary progressive MS (PPMS) from the pivotal ocrelizumab MS trials. NfL treatment-response and risk for disease worsening (including disability progression into the open-label extension period and slowly expanding lesions [SELs] on brain MRI) at baseline and following treatment with ocrelizumab were evaluated using time-to-event analysis and linear regression models.FindingsIn persons from the RMS control arms without acute disease activity and in the entire PPMS control arm, higher baseline NfL was prognostic for greater whole brain and thalamic atrophy, greater volume expansion of SELs, and clinical progression. Ocrelizumab reduced NfL levels vs. controls in persons with RMS and those with PPMS, and abrogated the prognostic value of baseline NfL on disability progression. Following effective suppression of relapse activity by ocrelizumab, NfL levels at weeks 24 and 48 were significantly associated with long-term risk for disability progression, including up to 9 years of observation in RMS and PPMS.InterpretationHighly elevated NfL from acute MS disease activity may mask a more subtle NfL abnormality that reflects underlying non-relapsing progressive biology. Ocrelizumab significantly reduced NfL levels, consistent with its effects on acute disease activity and disability progression. Persistently elevated NfL levels, observed in a subgroup of persons under ocrelizumab treatment, demonstrate potential clinical utility as a predictive biomarker of increased risk for clinical progression. Suppression of relapsing biology with high-efficacy immunotherapy provides a window into the relationship between NfL levels and future non-relapsing progression.FundingF. Hoffmann-La Roche Ltd.
- Published
- 2023
10. Neural correlates of digital measures shown by structural MRI: a post-hoc analysis of a smartphone-based remote assessment feasibility study in multiple sclerosis
- Author
-
Ganzetti, Marco, Graves, Jennifer S, Holm, Sven P, Dondelinger, Frank, Midaglia, Luciana, Gaetano, Laura, Craveiro, Licinio, Lipsmeier, Florian, Bernasconi, Corrado, Montalban, Xavier, Hauser, Stephen L, and Lindemann, Michael
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Clinical Sciences ,Clinical Research ,Clinical Trials and Supportive Activities ,Brain Disorders ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Neurological ,Humans ,Multiple Sclerosis ,Smartphone ,Feasibility Studies ,Magnetic Resonance Imaging ,Brain ,Multiple sclerosis ,Smartphone sensor ,MRI ,Neural correlates ,Digital health technology tools ,Neurology & Neurosurgery ,Clinical sciences - Abstract
BackgroundA study was undertaken to evaluate remote monitoring via smartphone sensor-based tests in people with multiple sclerosis (PwMS). This analysis aimed to explore regional neural correlates of digital measures derived from these tests.MethodsIn a 24-week, non-randomized, interventional, feasibility study (NCT02952911), sensor-based tests on the Floodlight Proof-of-Concept app were used to assess cognition (smartphone-based electronic Symbol Digit Modalities Test), upper extremity function (Draw a Shape Test, Pinching Test), and gait and balance (Static Balance Test, Two-Minute Walk Test, U-Turn Test). In this post-hoc analysis, digital measures and standard clinical measures (e.g., Nine-Hole Peg Test [9HPT]) were correlated against regional structural magnetic resonance imaging outcomes. Seventy-six PwMS aged 18-55 years with an Expanded Disability Status Scale score of 0.0-5.5 were enrolled from two different sites (USA and Spain). Sixty-two PwMS were included in this analysis.ResultsWorse performance on digital and clinical measures was associated with smaller regional brain volumes and larger ventricular volumes. Whereas digital and clinical measures had many neural correlates in common (e.g., putamen, globus pallidus, caudate nucleus, lateral occipital cortex), some were observed only for digital measures. For example, Draw a Shape Test and Pinching Test measures, but not 9HPT score, correlated with volume of the hippocampus (r = 0.37 [drawing accuracy over time on the Draw a Shape Test]/ - 0.45 [touching asynchrony on the Pinching Test]), thalamus (r = 0.38/ - 0.41), and pons (r = 0.35/ - 0.35).ConclusionsMultiple neural correlates were identified for the digital measures in a cohort of people with early MS. Digital measures showed associations with brain regions that clinical measures were unable to demonstrate, thus providing potential novel information on functional ability compared with standard clinical assessments.
- Published
- 2023
11. Association of daily physical activity with brain volumes and cervical spinal cord areas in multiple sclerosis.
- Author
-
Block, Valerie J, Cheng, Shuiting, Juwono, Jeremy, Cuneo, Richard, Kirkish, Gina, Alexander, Amber M, Khan, Mahir, Akula, Amit, Caverzasi, Eduardo, Papinutto, Nico, Stern, William A, Pletcher, Mark J, Marcus, Gregory M, Olgin, Jeffrey E, Hauser, Stephen L, Gelfand, Jeffrey M, Bove, Riley, Cree, Bruce Ac, and Henry, Roland G
- Subjects
Brain ,Spinal Cord ,Humans ,Multiple Sclerosis ,Atrophy ,Magnetic Resonance Imaging ,Disability Evaluation ,Walking ,Adult ,Middle Aged ,Disabled Persons ,Cervical Cord ,Motor Disorders ,Fitbit ,Multiple sclerosis ,activity level ,brain MRI ,cervical MRI ,remote monitoring ,spinal cord gray matter area ,Biomedical Imaging ,Brain Disorders ,Neurosciences ,Physical Rehabilitation ,Physical Injury - Accidents and Adverse Effects ,Neurodegenerative ,Spinal Cord Injury ,Clinical Research ,Autoimmune Disease ,Traumatic Head and Spine Injury ,Rehabilitation ,Neurological ,Clinical Sciences ,Neurology & Neurosurgery - Abstract
BackgroundRemote activity monitoring has the potential to evaluate real-world, motor function, and disability at home. The relationships of daily physical activity with spinal cord white matter and gray matter (GM) areas, multiple sclerosis (MS) disability and leg function, are unknown.ObjectiveEvaluate the association of structural central nervous system pathology with ambulatory disability.MethodsFifty adults with progressive or relapsing MS with motor disability who could walk >2 minutes were assessed using clinician-evaluated, patient-reported outcomes, and quantitative brain and spinal cord magnetic resonance imaging (MRI) measures. Fitbit Flex2, worn on the non-dominant wrist, remotely assessed activity over 30 days. Univariate and multivariate analyses were performed to assess correlations between physical activity and other disability metrics.ResultsMean age was 53.3 years and median Expanded Disability Status Scale (EDSS) was 4.0. Average daily step counts (STEPS) were highly correlated with EDSS and walking measures. Greater STEPS were significantly correlated with greater C2-C3 spinal cord GM areas (ρ = 0.39, p = 0.04), total cord area (TCA; ρ = 0.35, p = 0.04), and cortical GM volume (ρ = 0.32, p = 0.04).ConclusionThese results provide preliminary evidence that spinal cord GM area is a neuroanatomical substrate associated with STEPS. STEPS could serve as a proxy to alert clinicians and researchers to possible changes in structural nervous system pathology.
- Published
- 2023
12. Remote Observational Research for Multiple Sclerosis
- Author
-
Bove, Riley, Poole, Shane, Cuneo, Richard, Gupta, Sasha, Sabatino, Joseph, Harms, Meagan, Cooper, Tifffany, Rowles, William, Miller, Nicolette, Gomez, Refujia, Lincoln, Robin, McPolin, Kira, Powers, Kyra, Santaniello, Adam, Renschen, Adam, Bevan, Carolyn J, Gelfand, Jeffrey M, Goodin, Douglas S, Guo, Chu-Yueh, Romeo, Andrew R, Hauser, Stephen L, and Cree, Bruce Anthony Campbell
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Neurodegenerative ,Neurosciences ,Multiple Sclerosis ,Brain Disorders ,Humans ,Prospective Studies ,Cross-Sectional Studies ,Pandemics ,COVID-19 ,UCSF MS-EPIC Team - Abstract
Background and objectivesProspective, deeply phenotyped research cohorts monitoring individuals with chronic neurologic conditions, such as multiple sclerosis (MS), depend on continued participant engagement. The COVID-19 pandemic restricted in-clinic research activities, threatening this longitudinal engagement, but also forced adoption of televideo-enabled care. This offered a natural experiment in which to analyze key dimensions of remote research: (1) comparison of remote vs in-clinic visit costs from multiple perspectives and (2) comparison of the remote with in-clinic measures in cross-sectional and longitudinal disability evaluations.MethodsBetween March 2020 and December 2021, 207 MS cohort participants underwent hybrid in-clinic and virtual research visits; 96 contributed 100 "matched visits," that is, in-clinic (Neurostatus-Expanded Disability Status Scale [NS-EDSS]) and remote (televideo-enabled EDSS [tele-EDSS]; electronic patient-reported EDSS [ePR-EDSS]) evaluations. Clinical, demographic, and socioeconomic characteristics of participants were collected.ResultsThe costs of remote visits were lower than in-clinic visits for research investigators (facilities, personnel, parking, participant compensation) but also for participants (travel, caregiver time) and carbon footprint (p < 0.05 for each). Median cohort EDSS was similar between the 3 modalities (NS-EDSS: 2, tele-EDSS: 1.5, ePR-EDSS: 2, range 0.6.5); the remote evaluations were each noninferior to the NS-EDSS within ±0.5 EDSS point (TOST for noninferiority, p < 0.01 for each). Furthermore, year to year, the % of participants with worsening/stable/improved EDSS scores was similar, whether each annual evaluation used NS-EDSS or whether it switched from NS-EDSS to tele-EDSS.DiscussionAltogether, the current findings suggest that remote evaluations can reduce the costs of research participation for patients, while providing a reasonable evaluation of disability trajectory longitudinally. This could inform the design of remote research that is more inclusive of diverse participants.
- Published
- 2023
13. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
- Author
-
Hauser, Stephen L, Bar-Or, Amit, Weber, Martin S, Kletzl, Heidemarie, Günther, Andreas, Manfrini, Marianna, Model, Fabian, Mercier, Francois, Petry, Claire, Wing, Qing, Koendgen, Harold, Smith, Terence, and Kappos, Ludwig
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Brain Disorders ,Clinical Research ,Neurodegenerative ,Neurosciences ,Multiple Sclerosis ,Autoimmune Disease ,Neurological ,Humans ,Antibodies ,Monoclonal ,Humanized ,Immunologic Factors ,Interferon beta-1a ,Recurrence - Abstract
Background and objectivesOcrelizumab improved clinical and MRI measures of disease activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses demonstrated a correlation between the ocrelizumab serum concentration and the degree of blood B-cell depletion, and body weight was identified as the most influential covariate on ocrelizumab pharmacokinetics. The magnitude of ocrelizumab treatment benefit on disability progression was greater in lighter vs heavier patients. These observations suggest that higher ocrelizumab serum levels provide more complete B-cell depletion and a greater delay in disability progression. The current post hoc analyses assessed population exposure-efficacy/safety relationships of ocrelizumab in patients with relapsing and primary progressive MS.MethodsPatients in OPERA I/II and ORATORIO were grouped in exposure quartiles based on their observed individual serum ocrelizumab level over the treatment period. Exposure-response relationships were analyzed for clinical efficacy (24-week confirmed disability progression (CDP), annualized relapse rate [ARR], and MRI outcomes) and adverse events.ResultsOcrelizumab reduced new MRI lesion counts to nearly undetectable levels in patients with relapsing or primary progressive MS across all exposure subgroups, and reduced ARR in patients with relapsing MS to very low levels (0.13-0.18). A consistent trend of higher ocrelizumab exposure leading to lower rates of CDP was seen (0%-25% [lowest] to 75%-100% [highest] quartile hazard ratios and 95% confidence intervals; relapsing MS: 0.70 [0.41-1.19], 0.85 [0.52-1.39], 0.47 [0.25-0.87], and 0.34 [0.17-0.70] vs interferon β-1a; primary progressive MS: 0.88 [0.59-1.30], 0.86 [0.60-1.25], 0.77 [0.52-1.14], and 0.55 [0.36-0.83] vs placebo). Infusion-related reactions, serious adverse events, and serious infections were similar across exposure subgroups.DiscussionThe almost complete reduction of ARR and MRI activity already evident in the lowest quartile, and across all ocrelizumab-exposure groups, suggests a ceiling effect. A consistent trend of higher ocrelizumab exposure leading to greater reduction in risk of CDP was observed, particularly in the relapsing MS trials, and was not associated with a higher rate of adverse events. Higher ocrelizumab exposure may provide improved control of disability progression by reducing disease activity below that detectable by ARR and MRI, and/or by attenuating other B-cell-related pathologies responsible for tissue damage.Classification of evidenceThis analysis provides Class III evidence that higher ocrelizumab serum levels are related to greater reduction in risk of disability progression in patients with multiple sclerosis. The study is rated Class III because of the initial treatment randomization disclosure that occurred after inclusion in the open-label extension.Trial registration informationClinicalTrials.gov Identifier: NCT01247324 (OPERA I), NCT01412333 (OPERA II), and NCT01194570 (ORATORIO).
- Published
- 2023
14. Integration of epigenetic and genetic profiles identifies multiple sclerosis disease-critical cell types and genes.
- Author
-
Ma, Qin, Shams, Hengameh, Didonna, Alessandro, Baranzini, Sergio E, Cree, Bruce AC, Hauser, Stephen L, Henry, Roland G, and Oksenberg, Jorge R
- Subjects
Humans ,Multiple Sclerosis ,Risk Factors ,Epigenesis ,Genetic ,Genome-Wide Association Study ,Genetic Profile ,Prevention ,Human Genome ,Clinical Research ,Autoimmune Disease ,Genetics ,Neurodegenerative ,Neurosciences ,Brain Disorders ,Aetiology ,2.1 Biological and endogenous factors ,Inflammatory and immune system ,Neurological - Abstract
Genome-wide association studies (GWAS) successfully identified multiple sclerosis (MS) susceptibility variants. Despite this notable progress, understanding the biological context of these associations remains challenging, due in part to the complexity of linking GWAS results to causative genes and cell types. Here, we aimed to address this gap by integrating GWAS data with single-cell and bulk chromatin accessibility data and histone modification profiles from immune and nervous systems. MS-GWAS associations are significantly enriched in regulatory regions of microglia and peripheral immune cell subtypes, especially B cells and monocytes. Cell-specific polygenic risk scores were developed to examine the cumulative impact of the susceptibility genes on MS risk and clinical phenotypes, showing significant associations with risk and brain white matter volume. The findings reveal enrichment of GWAS signals in B cell and monocyte/microglial cell-types, consistent with the known pathology and presumed targets of effective MS therapeutics.
- Published
- 2023
15. Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans.
- Author
-
Shams, Hengameh, Shao, Xiaorong, Santaniello, Adam, Kirkish, Gina, Harroud, Adil, Ma, Qin, Isobe, Noriko, University of California San Francisco MS-EPIC Team, Schaefer, Catherine A, McCauley, Jacob L, Cree, Bruce AC, Didonna, Alessandro, Baranzini, Sergio E, Patsopoulos, Nikolaos A, Hauser, Stephen L, Barcellos, Lisa F, Henry, Roland G, and Oksenberg, Jorge R
- Subjects
University of California San Francisco MS-EPIC Team ,Humans ,Multiple Sclerosis ,Genetic Predisposition to Disease ,Risk Factors ,Epigenesis ,Genetic ,Multifactorial Inheritance ,Phenotype ,Genome-Wide Association Study ,European People ,multiple sclerosis ,pathway-specific risk score ,phenotype association ,polygenic risk score ,Brain Disorders ,Neurodegenerative ,Autoimmune Disease ,Human Genome ,Neurosciences ,Prevention ,Genetics ,2.1 Biological and endogenous factors ,Aetiology ,Good Health and Well Being ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Neurology & Neurosurgery - Abstract
Polygenic inheritance plays a pivotal role in driving multiple sclerosis susceptibility, an inflammatory demyelinating disease of the CNS. We developed polygenic risk scores (PRS) of multiple sclerosis and assessed associations with both disease status and severity in cohorts of European descent. The largest genome-wide association dataset for multiple sclerosis to date (n = 41 505) was leveraged to generate PRS scores, serving as an informative susceptibility marker, tested in two independent datasets, UK Biobank [area under the curve (AUC) = 0.73, 95% confidence interval (CI): 0.72-0.74, P = 6.41 × 10-146] and Kaiser Permanente in Northern California (KPNC, AUC = 0.8, 95% CI: 0.76-0.82, P = 1.5 × 10-53). Individuals within the top 10% of PRS were at higher than 5-fold increased risk in UK Biobank (95% CI: 4.7-6, P = 2.8 × 10-45) and 15-fold higher risk in KPNC (95% CI: 10.4-24, P = 3.7 × 10-11), relative to the median decile. The cumulative absolute risk of developing multiple sclerosis from age 20 onwards was significantly higher in genetically predisposed individuals according to PRS. Furthermore, inclusion of PRS in clinical risk models increased the risk discrimination by 13% to 26% over models based only on conventional risk factors in UK Biobank and KPNC, respectively. Stratifying disease risk by gene sets representative of curated cellular signalling cascades, nominated promising genetic candidate programmes for functional characterization. These pathways include inflammatory signalling mediation, response to viral infection, oxidative damage, RNA polymerase transcription, and epigenetic regulation of gene expression to be among significant contributors to multiple sclerosis susceptibility. This study also indicates that PRS is a useful measure for estimating susceptibility within related individuals in multicase families. We show a significant association of genetic predisposition with thalamic atrophy within 10 years of disease progression in the UCSF-EPIC cohort (P < 0.001), consistent with a partial overlap between the genetics of susceptibility and end-organ tissue injury. Mendelian randomization analysis suggested an effect of multiple sclerosis susceptibility on thalamic volume, which was further indicated to be through horizontal pleiotropy rather than a causal effect. In summary, this study indicates important, replicable associations of PRS with enhanced risk assessment and radiographic outcomes of tissue injury, potentially informing targeted screening and prevention strategies.
- Published
- 2023
16. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II
- Author
-
Gärtner, Jutta, Hauser, Stephen L, Bar-Or, Amit, Montalban, Xavier, Cohen, Jeffrey A, Cross, Anne H, Deiva, Kumaran, Ganjgahi, Habib, Häring, Dieter A, Li, Bingbing, Pingili, Ratnakar, Ramanathan, Krishnan, Su, Wendy, Willi, Roman, Kieseier, Bernd, and Kappos, Ludwig
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Clinical Trials and Supportive Activities ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Antibodies ,Monoclonal ,Humanized ,Humans ,Multiple Sclerosis ,Multiple Sclerosis ,Relapsing-Remitting ,Recurrence ,Toluidines ,Relapsing multiple sclerosis ,recently diagnosed ,treatment-naive ,progression independent of relapse activity ,no evidence of disease activity ,neurofilament light chain ,Neurosciences ,Neurology & Neurosurgery ,Clinical sciences ,Biological psychology - Abstract
BackgroundIn the phase III ASCLEPIOS I and II trials, participants with relapsing multiple sclerosis receiving ofatumumab had significantly better clinical and magnetic resonance imaging (MRI) outcomes than those receiving teriflunomide.ObjectivesTo assess the efficacy and safety of ofatumumab versus teriflunomide in recently diagnosed, treatment-naive (RDTN) participants from ASCLEPIOS.MethodsParticipants were randomized to receive ofatumumab (20 mg subcutaneously every 4 weeks) or teriflunomide (14 mg orally once daily) for up to 30 months. Endpoints analysed post hoc in the protocol-defined RDTN population included annualized relapse rate (ARR), confirmed disability worsening (CDW), progression independent of relapse activity (PIRA) and adverse events.ResultsData were analysed from 615 RDTN participants (ofatumumab: n = 314; teriflunomide: n = 301). Compared with teriflunomide, ofatumumab reduced ARR by 50% (rate ratio (95% confidence interval (CI)): 0.50 (0.33, 0.74); p
- Published
- 2022
17. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
- Author
-
Hauser, Stephen L, Cross, Anne H, Winthrop, Kevin, Wiendl, Heinz, Nicholas, Jacqueline, Meuth, Sven G, Giacomini, Paul S, Saccà, Francesco, Mancione, Linda, Zielman, Ronald, Bagger, Morten, Gupta, Ayan Das, Häring, Dieter A, Jehl, Valentine, Kieseier, Bernd C, Pingili, Ratnakar, Stoneman, Dee, Su, Wendy, Willi, Roman, and Kappos, Ludwig
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Rare Diseases ,Patient Safety ,Infectious Diseases ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Antibodies ,Monoclonal ,Humanized ,Humans ,Multiple Sclerosis ,Multiple Sclerosis ,Relapsing-Remitting ,Ofatumumab ,multiple sclerosis ,antibodies ,monoclonal ,relapsing multiple sclerosis ,safety ,Neurosciences ,Neurology & Neurosurgery ,Clinical sciences ,Biological psychology - Abstract
BackgroundOfatumumab is approved for the treatment of relapsing multiple sclerosis (RMS). Ongoing safety reporting is crucial to understand its long-term benefit-risk profile.ObjectiveReport the safety and tolerability of ofatumumab in RMS after extended treatment up to 3.5 years.MethodsPatients completing ASCLEPIOS I/II (phase 3), APLIOS, or APOLITOS (phase 2) trials could enter ALITHIOS, a phase 3b, open-label, long-term safety study. We analyzed cumulative data of continuous ofatumumab treatment and of patients newly switched from teriflunomide.ResultsThe safety population had 1969 patients: 1292 continuously treated with ofatumumab (median time-at-risk 35.5 months, 3253 patient-years) and 677 newly switched (median time-at-risk 18.3 months, 986 patient-years). A total of 1650 patients (83.8%) had ⩾1 adverse events and 191 (9.7%) had ⩾1 serious adverse events. No opportunistic infections or progressive multifocal leukoencephalopathy events were identified; the risk of malignancies was low. Mean serum immunoglobulin (Ig) G levels remained stable. Mean IgM levels decreased but remained above the lower limit of normal in most. Serious infection incidence was low; decreased Ig levels were not associated with serious infections.ConclusionIn patients with up to 3.5 years' exposure, ofatumumab was well tolerated, with no new safety risks identified. These findings, with its established effectiveness, support a favorable benefit-risk profile of ofatumumab in RMS.
- Published
- 2022
18. A smartphone sensor-based digital outcome assessment of multiple sclerosis
- Author
-
Montalban, Xavier, Graves, Jennifer, Midaglia, Luciana, Mulero, Patricia, Julian, Laura, Baker, Michael, Schadrack, Jan, Gossens, Christian, Ganzetti, Marco, Scotland, Alf, Lipsmeier, Florian, van Beek, Johan, Bernasconi, Corrado, Belachew, Shibeshih, Lindemann, Michael, and Hauser, Stephen L
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Autoimmune Disease ,Neurodegenerative ,Multiple Sclerosis ,Clinical Research ,Brain Disorders ,Neurosciences ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Neurological ,Gait ,Humans ,Outcome Assessment ,Health Care ,Reproducibility of Results ,Smartphone ,Multiple sclerosis ,smartphone ,sensors ,digital health technology ,wearable electronic devices ,mobile phone ,Neurology & Neurosurgery ,Clinical sciences ,Biological psychology - Abstract
BackgroundSensor-based monitoring tools fill a critical gap in multiple sclerosis (MS) research and clinical care.ObjectiveThe aim of this study is to assess performance characteristics of the Floodlight Proof-of-Concept (PoC) app.MethodsIn a 24-week study (clinicaltrials.gov: NCT02952911), smartphone-based active tests and passive monitoring assessed cognition (electronic Symbol Digit Modalities Test), upper extremity function (Pinching Test, Draw a Shape Test), and gait and balance (Static Balance Test, U-Turn Test, Walk Test, Passive Monitoring). Intraclass correlation coefficients (ICCs) and age- or sex-adjusted Spearman's rank correlation determined test-retest reliability and correlations with clinical and magnetic resonance imaging (MRI) outcome measures, respectively.ResultsSeventy-six people with MS (PwMS) and 25 healthy controls were enrolled. In PwMS, ICCs were moderate-to-good (ICC(2,1) = 0.61-0.85) across tests. Correlations with domain-specific standard clinical disability measures were significant for all tests in the cognitive (r = 0.82, p < 0.001), upper extremity function (|r|= 0.40-0.64, all p < 0.001), and gait and balance domains (r = -0.25 to -0.52, all p < 0.05; except for Static Balance Test: r = -0.20, p > 0.05). Most tests also correlated with Expanded Disability Status Scale, 29-item Multiple Sclerosis Impact Scale items or subscales, and/or normalized brain volume.ConclusionThe Floodlight PoC app captures reliable and clinically relevant measures of functional impairment in MS, supporting its potential use in clinical research and practice.
- Published
- 2022
19. Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
- Author
-
Butzkueven, Helmut, Spelman, Tim, Horakova, Dana, Hughes, Stella, Solaro, Claudio, Izquierdo, Guillermo, Havrdová, Eva Kubala, Grand'Maison, Francois, Prat, Alexandre, Girard, Marc, Hupperts, Raymond, Onofrj, Marco, Lugaresi, Alessandra, Taylor, Bruce, Group, the MSBase Study, Giovannoni, Gavin, Kappos, Ludwig, Hauser, Stephen L, Montalban, Xavier, Craveiro, Licinio, Freitas, Rita, Model, Fabian, Overell, James, Rouzic, Erwan Muros‐Le, Sauter, Annette, Wang, Qing, Wormser, David, and Wolinsky, Jerry S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Rehabilitation ,Clinical Trials and Supportive Activities ,Neurosciences ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Disease Progression ,Humans ,Multiple Sclerosis ,Multiple Sclerosis ,Chronic Progressive ,Registries ,Wheelchairs ,disease progression ,ocrelizumab ,primary progressive multiple sclerosis ,wheelchair ,MSBase Study Group ,Neurology & Neurosurgery ,Clinical sciences - Abstract
Background and purposeReaching Expanded Disability Status Scale (EDSS) ≥7.0 represents the requirement for a wheelchair. Here we (i) assess the effect of ocrelizumab on time to EDSS ≥7.0 over the ORATORIO (NCT01194570) double-blind and extended controlled periods (DBP+ECP), (ii) quantify likely long-term benefits by extrapolating results, and (iii) assess the plausibility of extrapolations using an independent real-world cohort (MSBase registry; ACTRN12605000455662).MethodsPost hoc analyses assessing time to 24-week confirmed EDSS ≥7.0 in two cohorts of patients with primary progressive multiple sclerosis (baseline EDSS 3.0-6.5) were investigated in ORATORIO and MSBase.ResultsIn the ORATORIO DBP+ECP, ocrelizumab reduced the risk of 24-week confirmed EDSS ≥7.0 (hazard ratio = 0.54, 95% confidence interval [CI]: 0.31-0.92; p = 0.022). Extrapolated median time to 24-week confirmed EDSS ≥7.0 was 12.1 and 19.2 years for placebo and ocrelizumab, respectively (7.1-year delay [95% CI: -4.3 to 18.4]). In MSBase, the median time to 24-week confirmed EDSS ≥7.0 was 12.4 years.ConclusionsCompared with placebo, ocrelizumab significantly delayed time to 24-week confirmed wheelchair requirement in ORATORIO. The plausibility of the extrapolated median time to reach this milestone in the placebo group was supported by observed real-world data from MSBase. Extrapolated benefits for ocrelizumab over placebo could represent a truly meaningful delay in loss of ambulation and independence.
- Published
- 2022
20. Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
- Author
-
Giovannoni, Gavin, Kappos, Ludwig, Seze, Jerome, Hauser, Stephen L, Overell, James, Koendgen, Harold, Manfrini, Marianna, Wang, Qing, and Wolinsky, Jerry S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Clinical Trials and Supportive Activities ,Neurosciences ,Multiple Sclerosis ,Brain Disorders ,Prevention ,Neurodegenerative ,Antibodies ,Monoclonal ,Humanized ,Humans ,Immunologic Factors ,Multiple Sclerosis ,Relapsing-Remitting ,Walking ,disease progression ,interferon beta 1a ,multiple sclerosis ,ocrelizumab ,walking stick ,Neurology & Neurosurgery ,Clinical sciences - Abstract
Background and purposeRequiring a walking aid is a fundamental milestone in multiple sclerosis (MS), represented by an Expanded Disability Status Scale (EDSS) score ≥6.0. In the present study, we assess the effect of ocrelizumab (OCR) on time to EDSS score ≥6.0 in relapsing MS.MethodsTime to EDSS score ≥6.0 confirmed for ≥24 and ≥48 weeks was assessed over the course of 6.5 years (336 weeks) in the double-blind period (DBP) and open-label extension (OLE) period of the OPERA I (NCT01247324) and OPERA II (NCT01412333) studies.ResultsTime to reach EDSS score ≥6.0 was significantly delayed in those initially randomized to OCR versus interferon. Over 6.5 years, the risk of requiring a walking aid confirmed for ≥24 weeks was 34% lower among those who initiated OCR earlier versus delayed treatment (average hazard ratio [HR] DBP + OLE 0.66, 95% confidence interval [CI] 0.45-0.95; p = 0.024); the risk of requiring a walking aid confirmed for ≥48 weeks was 46% lower (average HR DBP+OLE 0.54, 95% CI 0.35-0.83; p = 0.004).ConclusionThe reduced risk of requiring a walking aid in earlier initiators of OCR demonstrates the long-term implications of earlier highly effective treatment.
- Published
- 2022
21. Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis.
- Author
-
Bischof, Antje, Papinutto, Nico, Keshavan, Anisha, Rajesh, Anand, Kirkish, Gina, Zhang, Xinheng, Mallott, Jacob M, Asteggiano, Carlo, Sacco, Simone, Gundel, Tristan J, Zhao, Chao, Stern, William A, Caverzasi, Eduardo, Zhou, Yifan, Gomez, Refujia, Ragan, Nicholas R, Santaniello, Adam, Zhu, Alyssa H, Juwono, Jeremy, Bevan, Carolyn J, Bove, Riley M, Crabtree, Elizabeth, Gelfand, Jeffrey M, Goodin, Douglas S, Graves, Jennifer S, Green, Ari J, Oksenberg, Jorge R, Waubant, Emmanuelle, Wilson, Michael R, Zamvil, Scott S, University of California, San Francisco MS-EPIC Team, Cree, Bruce AC, Hauser, Stephen L, and Henry, Roland G
- Subjects
University of California ,San Francisco MS-EPIC Team ,Foramen Magnum ,Brain ,Spinal Cord ,Humans ,Multiple Sclerosis ,Relapsing-Remitting ,Atrophy ,Disease Progression ,Magnetic Resonance Imaging ,Prognosis ,Prospective Studies ,Predictive Value of Tests ,Adult ,Middle Aged ,Female ,Male ,Multiple Sclerosis ,Autoimmune Disease ,Neurosciences ,Brain Disorders ,Neurodegenerative ,Aetiology ,2.1 Biological and endogenous factors ,Neurological ,Clinical Sciences ,Neurology & Neurosurgery - Abstract
ObjectiveA major challenge in multiple sclerosis (MS) research is the understanding of silent progression and Progressive MS. Using a novel method to accurately capture upper cervical cord area from legacy brain MRI scans we aimed to study the role of spinal cord and brain atrophy for silent progression and conversion to secondary progressive disease (SPMS).MethodsFrom a single-center observational study, all RRMS (n = 360) and SPMS (n = 47) patients and 80 matched controls were evaluated. RRMS patient subsets who converted to SPMS (n = 54) or silently progressed (n = 159), respectively, during the 12-year observation period were compared to clinically matched RRMS patients remaining RRMS (n = 54) or stable (n = 147), respectively. From brain MRI, we assessed the value of brain and spinal cord measures to predict silent progression and SPMS conversion.ResultsPatients who developed SPMS showed faster cord atrophy rates (-2.19%/yr) at least 4 years before conversion compared to their RRMS matches (-0.88%/yr, p
- Published
- 2022
22. Simultaneous assessment of regional distributions of atrophy across the neuraxis in MS patients
- Author
-
Freund, Patrick, Papinutto, Nico, Bischof, Antje, Azzarito, Michela, Kirkish, Gina, Ashburner, John, Thompson, Alan, Hauser, Stephen L, and Henry, Roland G
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Multiple Sclerosis ,Clinical Research ,Biomedical Imaging ,Neurodegenerative ,Brain Disorders ,Traumatic Head and Spine Injury ,Autoimmune Disease ,Neurosciences ,Spinal Cord Injury ,Physical Injury - Accidents and Adverse Effects ,Neurological ,Atrophy ,Cervical Cord ,Humans ,Magnetic Resonance Imaging ,Spinal Cord ,Biological psychology ,Clinical and health psychology - Abstract
BackgroundThe ability to assess brain and cord atrophy simultaneously would improve the efficiency of MRI to track disease evolution.ObjectiveTo test a promising tool to simultaneously map the regional distribution of atrophy in multiple sclerosis (MS) patients across the brain and cord.MethodsVoxel-based morphometry combined with a statistical parametric mapping probabilistic brain-spinal cord (SPM-BSC) template was applied to standard T1-weighted magnetic resonance imaging (MRI) scans covering the brain and cervical cord from 37 MS patients and 20 healthy controls (HC). We also measured the cord area at C2-C3 with a semi-automatic segmentation method using (i) the same T1-weighted acquisitions used for the new voxel-based analysis and (ii) dedicated spinal cord phase sensitive inversion recovery (PSIR) acquisitions. Cervical cord findings derived from the three approaches were compared to each other and the goodness to fit to clinical scores was assessed by regression analyses.ResultsThe SPM-BSC approach revealed a severity-dependent pattern of atrophy across the cervical cord and thalamus in MS patients when compared to HCs. The magnitude of cord atrophy was confirmed by the semi-automatic extraction approach at C2-C3 using both standard brain T1-weighted and advanced cord dedicated acquisitions. Associations between atrophy of cord and thalamus with disability and cognition were demonstrated.ConclusionAtrophy in the brain and cervical cord of MS patients can be identified simultaneously and rapidly at the voxel-level. The SPM-BSC approach yields similar results as available standard processing tools with the added advantage of performing the analysis simultaneously and faster.
- Published
- 2022
23. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials
- Author
-
Ziemssen, Tjalf, Arnold, Douglas L, Alvarez, Enrique, Cross, Anne H, Willi, Roman, Li, Bingbing, Kukkaro, Petra, Kropshofer, Harald, Ramanathan, Krishnan, Merschhemke, Martin, Kieseier, Bernd, Su, Wendy, Häring, Dieter A, Hauser, Stephen L, Kappos, Ludwig, and Kuhle, Jens
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Neurosciences ,Clinical Trials and Supportive Activities ,Gray Matter ,Humans ,Intermediate Filaments ,Multiple Sclerosis ,Prognosis ,Recurrence ,serum neurofilament light chain ,prognostic biomarker ,MS disease activity ,lesion formation ,brain atrophy ,Immunology ,Medical Microbiology ,Biochemistry and cell biology ,Genetics - Abstract
ObjectiveThis study aims to confirm the prognostic value of baseline serum neurofilament light chain (sNfL) for on-study disease activity and worsening in patients with relapsing MS (RMS).BackgroundPrevious post-hoc studies suggested that sNfL could be a prognostic biomarker in RMS. In the phase 3 ASCLEPIOS I/II trials in which ofatumumab demonstrated better efficacy outcomes than teriflunomide, treatment with ofatumumab also led to significantly reduced sNfL levels compared to teriflunomide treatment.Design/methodsIn this study, we report protocol-planned analyses from the pooled ASCLEPIOS I/II trials (N=1882). Per protocol, patients were stratified by median baseline sNfL levels (9.3 pg/ml) into high (>median) and low (≤median) categories to prognosticate: annualized rate of new/enlarging T2 (neT2) lesions in year 1 and 2, annualized relapse rate, annual percentage change in whole brain (WB) and regional brain volume [thalamus, white matter (WM), cortical gray matter (cGM)], and disability outcomes. Similar analyses were performed for the recently diagnosed (within 3 years), treatment-naive patients (no prior disease-modifying therapy) subgroup.ResultsHigh versus low sNfL at baseline was prognostic of increased on-study T2 lesion formation at year 1 (relative increase: ofatumumab +158%; teriflunomide +69%, both p
- Published
- 2022
24. Specific hypomethylation programs underpin B cell activation in early multiple sclerosis.
- Author
-
Ma, Qin, Caillier, Stacy J, Muzic, Shaun, University of California San Francisco MS-EPIC Team, Wilson, Michael R, Henry, Roland G, Cree, Bruce AC, Hauser, Stephen L, Didonna, Alessandro, and Oksenberg, Jorge R
- Subjects
University of California San Francisco MS-EPIC Team ,B-Lymphocytes ,Humans ,Multiple Sclerosis ,Gene Expression Profiling ,Lymphocyte Activation ,Cell Differentiation ,DNA Methylation ,Epigenesis ,Genetic ,Female ,Transcriptional Activation ,Genome-Wide Association Study ,Epigenomics ,B cell ,hypomethylation ,multiple sclerosis ,Brain Disorders ,Genetics ,Biotechnology ,Neurosciences ,Human Genome ,Neurodegenerative ,Autoimmune Disease ,2.1 Biological and endogenous factors ,Aetiology ,Neurological - Abstract
Epigenetic changes have been consistently detected in different cell types in multiple sclerosis (MS). However, their contribution to MS pathogenesis remains poorly understood partly because of sample heterogeneity and limited coverage of array-based methods. To fill this gap, we conducted a comprehensive analysis of genome-wide DNA methylation patterns in four peripheral immune cell populations isolated from 29 MS patients at clinical disease onset and 24 healthy controls. We show that B cells from new-onset untreated MS cases display more significant methylation changes than other disease-implicated immune cell types, consisting of a global DNA hypomethylation signature. Importantly, 4,933 MS-associated differentially methylated regions in B cells were identified, and this epigenetic signature underlies specific genetic programs involved in B cell differentiation and activation. Integration of the methylome to changes in gene expression and susceptibility-associated regions further indicates that hypomethylated regions are significantly associated with the up-regulation of cell activation transcriptional programs. Altogether, these findings implicate aberrant B cell function in MS etiology.
- Published
- 2021
25. Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
- Author
-
Hauser, Stephen L, Kappos, Ludwig, Montalban, Xavier, Craveiro, Licinio, Chognot, Cathy, Hughes, Richard, Koendgen, Harold, Pasquarelli, Noemi, Pradhan, Ashish, Prajapati, Kalpesh, and Wolinsky, Jerry S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Brain Disorders ,Multiple Sclerosis ,Neurodegenerative ,Clinical Trials and Supportive Activities ,Patient Safety ,Neurosciences ,Adolescent ,Adult ,Aged ,Antibodies ,Monoclonal ,Humanized ,Clinical Trials as Topic ,Drug-Related Side Effects and Adverse Reactions ,Female ,Humans ,Male ,Middle Aged ,Multiple Sclerosis ,Chronic Progressive ,Multiple Sclerosis ,Relapsing-Remitting ,Young Adult ,Cognitive Sciences ,Neurology & Neurosurgery ,Clinical sciences - Abstract
Background and objectivesTo report safety of ocrelizumab (OCR) up to 7 years in patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) enrolled in clinical trials or treated in real-world postmarketing settings.MethodsSafety analyses are based on integrated clinical and laboratory data for all patients who received OCR in 11 clinical trials, including the controlled treatment and open-label extension (OLE) periods of the phase 2 and 3 trials, plus the phase 3b trials VELOCE, CHORDS, CASTING, OBOE, ENSEMBLE, CONSONANCE, and LIBERTO. For selected adverse events (AEs), additional postmarketing data were used. Incidence rates of serious infections (SIs) and malignancies were contextualized using multiple epidemiologic sources.ResultsAt data cutoff (January 2020), 5,680 patients with multiple sclerosis (MS) received OCR (18,218 patient-years [PY] of exposure) in clinical trials. Rates per 100 PY (95% confidence interval) of AEs (248; 246-251), serious AEs (7.3; 7.0-7.7), infusion-related reactions (25.9; 25.1-26.6), and infections (76.2; 74.9-77.4) were similar to those within the controlled treatment period of the phase 3 trials. Rates of the most common serious AEs, including SIs (2.01; 1.81-2.23) and malignancies (0.46; 0.37-0.57), were consistent with the ranges reported in epidemiologic data.DiscussionContinuous administration of OCR for up to 7 years in clinical trials, as well as its broader use for more than 3 years in the real-world setting, are associated with a favorable and manageable safety profile, without emerging safety concerns, in a heterogeneous MS population.Classification of evidenceThis analysis provides Class III evidence that long-term, continuous treatment with OCR has a consistent and favorable safety profile in patients with RMS and PPMS. This study is rated Class III because of the use of OLE data and historical controls.
- Published
- 2021
26. Electronic Health Record Technology Designed for the Clinical Encounter: MS NeuroShare.
- Author
-
Bove, Riley, Bruce, Christa A, Lunders, Chelsea K, Pearce, Jennifer R, Liu, Jacqueline, Schleimer, Erica, Hauser, Stephen L, Stewart, Walter F, and Jones, JB
- Subjects
Clinical Research ,Neurodegenerative ,Autoimmune Disease ,Multiple Sclerosis ,Health Services ,Brain Disorders ,Neurosciences ,7.1 Individual care needs ,Management of diseases and conditions ,7.3 Management and decision making ,Generic health relevance ,Good Health and Well Being - Abstract
ObjectiveAdvances in medical discoveries have bolstered expectations of precise and complete care, but delivering on such a promise for complex, chronic neurologic care delivery requires solving last-mile challenges. We describe the iterative human-centered design and pilot process for multiple sclerosis (MS) NeuroShare, a digital health solution that brings practical information to the point of care so that clinicians and patients with MS can view, discuss, and make informed decisions together.MethodsWe initiated a comprehensive human-centered process to iteratively design, develop, and implement a digital health solution for managing MS in the routine outpatient setting of the nonprofit Sutter Health system in Northern California. The human-centered codesign process included 3 phases: discovery and design, development, and implementation and pilot. Stakeholders included Sutter Health's Research Development and Dissemination team, academic domain experts, neurologists, patients with MS, and an advisory group.ResultsMS NeuroShare went live in November 2018. It included a patient- and clinician-facing web application that launches from the electronic health record, visually displays a patient's data relevant to MS, and prompts the clinician to comprehensively evaluate and treat the patient. Both patients and clinicians valued the ability to jointly view patient-generated and other data. Preliminary results suggest that MS NeuroShare promotes patient-clinician communication and more active patient participation in decision-making.ConclusionsLessons learned in the design and implementation of MS NeuroShare are broadly applicable to the design and implementation of digital tools aiming to improve the experience of delivering and receiving high-quality care for complex, neurologic conditions across large health systems.
- Published
- 2021
27. An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis.
- Author
-
Romeo, Andrew R, Rowles, William M, Schleimer, Erica S, Barba, Patrick, Hsu, Wan-Yu, Gomez, Refujia, Santaniello, Adam, Zhao, Chao, Pearce, Jennifer R, Jones, JB, Cree, Bruce C, Hauser, Stephen L, Gelfand, Jeffrey M, Stewart, Walter F, Goodin, Douglas S, and Bove, Riley M
- Subjects
Humans ,Multiple Sclerosis ,Disability Evaluation ,Electronics ,Adult ,Aged ,Aged ,80 and over ,Middle Aged ,Patient Reported Outcome Measures ,Multiple sclerosis ,disability ,eHealth ,patient-reported outcome measures ,Autoimmune Disease ,Neurosciences ,Brain Disorders ,Clinical Research ,Neurodegenerative ,7.1 Individual care needs ,Management of diseases and conditions ,Neurological ,Clinical Sciences ,Neurology & Neurosurgery - Abstract
BackgroundIn persons with multiple sclerosis (MS), the Expanded Disability Status Scale (EDSS) is the criterion standard for assessing disability, but its in-person nature constrains patient participation in research and clinical assessments.ObjectiveThe aim of this study was to develop and validate a scalable, electronic, unsupervised patient-reported EDSS (ePR-EDSS) that would capture MS-related disability across the spectrum of severity.MethodsWe enrolled 136 adult MS patients, split into a preliminary testing Cohort 1 (n = 50), and a validation Cohort 2 (n = 86), which was evenly distributed across EDSS groups. Each patient completed an ePR-EDSS either immediately before or after a MS clinician's Neurostatus EDSS evaluation.ResultsIn Cohort 2, mean age was 50.6 years (range = 26-80) and median EDSS was 3.5 (interquartile range (IQR) = [1.5, 5.5]). The ePR-EDSS and EDSS agreed within 1-point for 86% of examinations; kappa for agreement within 1-point was 0.85 (p
- Published
- 2021
28. Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
- Author
-
Gibiansky, Ekaterina, Petry, Claire, Mercier, Francois, Günther, Andreas, Herman, Ann, Kappos, Ludwig, Hauser, Stephen, Yamamoto, Yumi, Wang, Qing, Model, Fabian, and Kletzl, Heidemarie
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Multiple Sclerosis ,Neurosciences ,Autoimmune Disease ,Brain Disorders ,Neurodegenerative ,Antibodies ,Monoclonal ,Humanized ,Humans ,Immunologic Factors ,Multiple Sclerosis ,Chronic Progressive ,Multiple Sclerosis ,Relapsing-Remitting ,pharmacokinetic– ,pharmacodynamic ,pharmacodynamics ,population analysis ,multiple sclerosis ,neurology ,pharmacokinetic-pharmacodynamic ,Pharmacology and Pharmaceutical Sciences ,Pharmacology & Pharmacy ,Pharmacology and pharmaceutical sciences - Abstract
AimsOcrelizumab is a humanized monoclonal antibody that selectively targets CD20-positive B cells and is indicated for treatment of patients with relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The pharmacokinetics and pharmacodynamics of ocrelizumab in patients with RMS or PPMS were assessed.MethodsA population pharmacokinetic model was developed based on data from the Phase II study and the Phase III studies OPERA I and OPERA II in patients with RMS. Data from the ORATORIO Phase III study in patients with PPMS became available after model finalization and was used for external model evaluation.ResultsThe ocrelizumab serum concentration vs time course was accurately described by a 2-compartment model with time-dependent clearance. Body weight was found to be the main covariate. The area under the concentration-time curve over the dosing interval was estimated to be 26% higher for patients with RMS weighing 90 kg when compared with the 60-90 kg group. The terminal half-life of ocrelizumab was estimated as 26 days. The extent of B-cell depletion in blood, as the pharmacodynamic marker, was greater with increasing ocrelizumab exposure.ConclusionThe pharmacokinetics of ocrelizumab was described with pharmacokinetic parameters typical for an immunoglobulin G1 monoclonal antibody, with body weight as the main covariate. The pharmacokinetics and B-cell depletion in blood were comparable across the RMS and PPMS trials, and the extent of blood B-cell depletion was greater with higher exposure.
- Published
- 2021
29. Role of B Cells in Multiple Sclerosis and Related Disorders
- Author
-
Comi, Giancarlo, Bar‐Or, Amit, Lassmann, Hans, Uccelli, Antonio, Hartung, Hans‐Peter, Montalban, Xavier, Sørensen, Per Solberg, Hohlfeld, Reinhard, Hauser, Stephen L, and Foundation, Panel of the 27th Annual Meeting of the European Charcot
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Neurodegenerative ,Autoimmune Disease ,Multiple Sclerosis ,Neurosciences ,Brain Disorders ,Neurological ,Autoantibodies ,B-Lymphocytes ,Central Nervous System ,Humans ,T-Lymphocytes ,Expert Panel of the 27th Annual Meeting of the European Charcot Foundation ,Clinical Sciences ,Neurology & Neurosurgery ,Clinical sciences - Abstract
The success of clinical trials of selective B-cell depletion in patients with relapsing multiple sclerosis (MS) and primary progressive MS has led to a conceptual shift in the understanding of MS pathogenesis, away from the classical model in which T cells were the sole central actors and toward a more complex paradigm with B cells having an essential role in both the inflammatory and neurodegenerative components of the disease process. The role of B cells in MS was selected as the topic of the 27th Annual Meeting of the European Charcot Foundation. Results of the meeting are presented in this concise review, which recaps current concepts underlying the biology and therapeutic rationale behind B-cell-directed therapeutics in MS, and proposes strategies to optimize the use of existing anti-B-cell treatments and provide future directions for research in this area. ANN NEUROL 2021;89:13-23.
- Published
- 2021
30. High Resolution Haplotype Analyses of Classical HLA Genes in Families With Multiple Sclerosis Highlights the Role of HLA-DP Alleles in Disease Susceptibility
- Author
-
Osoegawa, Kazutoyo, Creary, Lisa E, Montero-Martín, Gonzalo, Mallempati, Kalyan C, Gangavarapu, Sridevi, Caillier, Stacy J, Santaniello, Adam, Isobe, Noriko, Hollenbach, Jill A, Hauser, Stephen L, Oksenberg, Jorge R, and Fernández-Viňa, Marcelo A
- Subjects
Autoimmune Disease ,Genetics ,Human Genome ,Brain Disorders ,Neurosciences ,Clinical Research ,2.1 Biological and endogenous factors ,Aetiology ,Adolescent ,Adult ,Alleles ,Case-Control Studies ,Child ,Female ,Genetic Predisposition to Disease ,Genotyping Techniques ,HLA-DP Antigens ,Haplotypes ,Humans ,Male ,Middle Aged ,Multiple Sclerosis ,multiple sclerosis ,family ,HLA ,haplotype ,transmission disequilibrium test ,case-control analysis ,Immunology ,Medical Microbiology - Abstract
Multiple sclerosis (MS) susceptibility shows strong genetic associations with HLA alleles and haplotypes. We genotyped 11 HLA genes in 477 non-Hispanic European MS patients and their 954 unaffected parents using a validated next-generation sequencing (NGS) methodology. HLA haplotypes were assigned unequivocally by tracing HLA allele transmissions. We explored HLA haplotype/allele associations with MS using the genotypic transmission disequilibrium test (gTDT) and multiallelic TDT (mTDT). We also conducted a case-control (CC) study with all patients and 2029 healthy unrelated ethnically matched controls. We performed separate analyses of 54 extended multi-case families by reviewing transmission of haplotype blocks. The haplotype fragment including DRB5*01:01:01~DRB1*15:01:01:01 was significantly associated with predisposition (gTDT: p < 2.20e-16; mTDT: p =1.61e-07; CC: p < 2.22e-16) as reported previously. A second risk allele, DPB1*104:01 (gTDT: p = 3.69e-03; mTDT: p = 2.99e-03; CC: p = 1.00e-02), independent from the haplotype bearing DRB1*15:01 was newly identified. The allele DRB1*01:01:01 showed significant protection (gTDT: p = 8.68e-06; mTDT: p = 4.50e-03; CC: p = 1.96e-06). Two DQB1 alleles, DQB1*03:01 (gTDT: p = 2.86e-03; mTDT: p = 5.56e-02; CC: p = 4.08e-05) and DQB1*03:03 (gTDT: p = 1.17e-02; mTDT: p = 1.16e-02; CC: p = 1.21e-02), defined at two-field level also showed protective effects. The HLA class I block, A*02:01:01:01~C*03:04:01:01~B*40:01:02 (gTDT: p = 5.86e-03; mTDT: p = 3.65e-02; CC: p = 9.69e-03) and the alleles B*27:05 (gTDT: p = 6.28e-04; mTDT: p = 2.15e-03; CC: p = 1.47e-02) and B*38:01 (gTDT: p = 3.20e-03; mTDT: p = 6.14e-03; CC: p = 1.70e-02) showed moderately protective effects independently from each other and from the class II associated factors. By comparing statistical significance of 11 HLA loci and 19 haplotype segments with both untruncated and two-field allele names, we precisely mapped MS candidate alleles/haplotypes while eliminating false signals resulting from 'hitchhiking' alleles. We assessed genetic burden for the HLA allele/haplotype identified in this study. This family-based study including the highest-resolution of HLA alleles proved to be powerful and efficient for precise identification of HLA genotypes associated with both, susceptibility and protection to development of MS.
- Published
- 2021
31. Treatment of Multiple Sclerosis: A Review
- Author
-
Hauser, Stephen L and Cree, Bruce AC
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Neurosciences ,Multiple Sclerosis ,Neurodegenerative ,Autoimmune Disease ,Brain Disorders ,7.1 Individual care needs ,Management of diseases and conditions ,Neurological ,Antibodies ,Monoclonal ,Humans ,Immunosuppressive Agents ,Physical Therapy Modalities ,B-cell therapy ,MS therapy ,Multiple sclerosis ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of the central nervous system, and the leading cause of nontraumatic neurological disability in young adults. Effective management requires a multifaceted approach to control acute attacks, manage progressive worsening, and remediate bothersome or disabling symptoms associated with this illness. Remarkable advances in treatment of all forms of MS, and especially for relapsing disease, have favorably changed the long-term outlook for many patients. There also has been a conceptual shift in understanding the immune pathology of MS, away from a purely T-cell-mediated model to recognition that B cells have a key role in pathogenesis. The emergence of higher-efficacy drugs requiring less frequent administration have made these preferred options in terms of tolerability and adherence. Many experts now recommend use of these as first-line treatment for many patients with early disease, before permanent disability is evident.
- Published
- 2020
32. Gut microbiota–specific IgA+ B cells traffic to the CNS in active multiple sclerosis
- Author
-
Pröbstel, Anne-Katrin, Zhou, Xiaoyuan, Baumann, Ryan, Wischnewski, Sven, Kutza, Michael, Rojas, Olga L, Sellrie, Katrin, Bischof, Antje, Kim, Kicheol, Ramesh, Akshaya, Dandekar, Ravi, Greenfield, Ariele L, Schubert, Ryan D, Bisanz, Jordan E, Vistnes, Stephanie, Khaleghi, Khashayar, Landefeld, James, Kirkish, Gina, Liesche-Starnecker, Friederike, Ramaglia, Valeria, Singh, Sneha, Tran, Edwina B, Barba, Patrick, Zorn, Kelsey, Oechtering, Johanna, Forsberg, Karin, Shiow, Lawrence R, Henry, Roland G, Graves, Jennifer, Cree, Bruce AC, Hauser, Stephen L, Kuhle, Jens, Gelfand, Jeffrey M, Andersen, Peter M, Schlegel, Jürgen, Turnbaugh, Peter J, Seeberger, Peter H, Gommerman, Jennifer L, Wilson, Michael R, Schirmer, Lucas, and Baranzini, Sergio E
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Neurosciences ,Multiple Sclerosis ,Neurodegenerative ,Microbiome ,Brain Disorders ,Autoimmune Disease ,Aetiology ,2.1 Biological and endogenous factors ,Neurological ,Good Health and Well Being ,Adult ,Aged ,Aged ,80 and over ,B-Lymphocytes ,Biomarkers ,Biopsy ,Brain ,Case-Control Studies ,Female ,Gastrointestinal Microbiome ,Humans ,Immunity ,Mucosal ,Immunoglobulin A ,Intestinal Mucosa ,Longitudinal Studies ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Clinical sciences - Abstract
Changes in gut microbiota composition and a diverse role of B cells have recently been implicated in multiple sclerosis (MS), a central nervous system (CNS) autoimmune disease. Immunoglobulin A (IgA) is a key regulator at the mucosal interface. However, whether gut microbiota shape IgA responses and what role IgA+ cells have in neuroinflammation are unknown. Here, we identify IgA-bound taxa in MS and show that IgA-producing cells specific for MS-associated taxa traffic to the inflamed CNS, resulting in a strong, compartmentalized IgA enrichment in active MS and other neuroinflammatory diseases. Unlike previously characterized polyreactive anti-commensal IgA responses, CNS IgA cross-reacts with surface structures on specific bacterial strains but not with brain tissue. These findings establish gut microbiota-specific IgA+ cells as a systemic mediator in MS and suggest a critical role of mucosal B cells during active neuroinflammation with broad implications for IgA as an informative biomarker and IgA-producing cells as an immune subset to harness for therapeutic interventions.
- Published
- 2020
33. Two genetic variants explain the association of European ancestry with multiple sclerosis risk in African-Americans.
- Author
-
Nakatsuka, Nathan, Patterson, Nick, Patsopoulos, Nikolaos A, Altemose, Nicolas, Tandon, Arti, Beecham, Ashley H, McCauley, Jacob L, Isobe, Noriko, Hauser, Stephen, De Jager, Philip L, Hafler, David A, Oksenberg, Jorge R, and Reich, David
- Subjects
Humans ,Multiple Sclerosis ,Genetic Predisposition to Disease ,Odds Ratio ,Haplotypes ,Polymorphism ,Single Nucleotide ,African Americans ,Female ,Male ,Genome-Wide Association Study ,Whites ,Black or African American ,White People ,Neurodegenerative ,Neurosciences ,Clinical Research ,Human Genome ,Autoimmune Disease ,Genetics ,Brain Disorders ,Aetiology ,2.1 Biological and endogenous factors - Abstract
Epidemiological studies have suggested differences in the rate of multiple sclerosis (MS) in individuals of European ancestry compared to African ancestry, motivating genetic scans to identify variants that could contribute to such patterns. In a whole-genome scan in 899 African-American cases and 1155 African-American controls, we confirm that African-Americans who inherit segments of the genome of European ancestry at a chromosome 1 locus are at increased risk for MS [logarithm of odds (LOD) = 9.8], although the signal weakens when adding an additional 406 cases, reflecting heterogeneity in the two sets of cases [logarithm of odds (LOD) = 2.7]. The association in the 899 individuals can be fully explained by two variants previously associated with MS in European ancestry individuals. These variants tag a MS susceptibility haplotype associated with decreased CD58 gene expression (odds ratio of 1.37; frequency of 84% in Europeans and 22% in West Africans for the tagging variant) as well as another haplotype near the FCRL3 gene (odds ratio of 1.07; frequency of 49% in Europeans and 8% in West Africans). Controlling for all other genetic and environmental factors, the two variants predict a 1.44-fold higher rate of MS in European-Americans compared to African-Americans.
- Published
- 2020
34. Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
- Author
-
Hauser, Stephen L, Kappos, Ludwig, Arnold, Douglas L, Bar-Or, Amit, Brochet, Bruno, Naismith, Robert T, Traboulsee, Anthony, Wolinsky, Jerry S, Belachew, Shibeshih, Koendgen, Harold, Levesque, Victoria, Manfrini, Marianna, Model, Fabian, Hubeaux, Stanislas, Mehta, Lahar, and Montalban, Xavier
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Neurosciences ,Brain Disorders ,Clinical Trials and Supportive Activities ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Neurological ,Adult ,Antibodies ,Monoclonal ,Humanized ,Brain ,Female ,Follow-Up Studies ,Humans ,Immunologic Factors ,Magnetic Resonance Imaging ,Male ,Multiple Sclerosis ,Relapsing-Remitting ,Neuroimaging ,Randomized Controlled Trials as Topic ,Recurrence ,Time Factors ,Treatment Outcome ,Cognitive Sciences ,Neurology & Neurosurgery ,Clinical sciences - Abstract
ObjectiveTo assess over 3 years of follow-up the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled OPERA: I/II studies in relapsing multiple sclerosis.MethodsAfter 2 years of double-blind, controlled treatment, patients continued OCR (600 mg infusions every 24 weeks) or switched from interferon (IFN)-β-1a (44 μg 3 times weekly) to OCR when entering the OLE phase (3 years). Adjusted annualized relapse rate, time to onset of 24-week confirmed disability progression (CDP)/improvement (CDP), brain MRI activity (gadolinium-enhanced and new/enlarging T2 lesions), and percentage brain volume change were analyzed.ResultsOf patients entering the OLE phase, 88.6% completed year 5. The cumulative proportion with 24-week CDP was lower in patients who initiated OCR earlier vs patients initially receiving IFN-β-1a (16.1% vs 21.3% at year 5; p = 0.014). Patients continuing OCR maintained and those switching from IFN-β-1a to OCR attained near complete and sustained suppression of new brain MRI lesion activity from years 3-5. Over the OLE phase, patients continuing OCR exhibited less whole brain volume loss from double-blind study baseline vs those switching from IFN-β-1a (-1.87% vs -2.15% at year 5; p < 0.01). Adverse events were consistent with past reports and no new safety signals emerged with prolonged treatment.ConclusionCompared with patients switching from IFN-β-1a, earlier and continuous OCR treatment up to 5 years provided sustained benefit on clinical and MRI measures of disease progression.Classification of evidenceThis study provides Class III evidence that earlier and continuous treatment with OCR provided sustained benefit on clinical and MRI outcomes of disease activity and progression compared with patients switching from IFN-β-1a. The study is rated Class III because of the initial treatment randomization disclosure that occurred after inclusion in OLE.Clinical trial identifiersNCT01247324/NCT01412333.
- Published
- 2020
35. A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis
- Author
-
Ramesh, Akshaya, Schubert, Ryan D, Greenfield, Ariele L, Dandekar, Ravi, Loudermilk, Rita, Sabatino, Joseph J, Koelzer, Matthew T, Tran, Edwina B, Koshal, Kanishka, Kim, Kicheol, Pröbstel, Anne-Katrin, Banerji, Debarko, San Francisco MS-EPIC Team University of California, Guo, Chu-Yueh, Green, Ari J, Bove, Riley M, DeRisi, Joseph L, Gelfand, Jeffrey M, Cree, Bruce AC, Zamvil, Scott S, Baranzini, Sergio E, Hauser, Stephen L, and Wilson, Michael R
- Subjects
Biotechnology ,Neurodegenerative ,Autoimmune Disease ,Genetics ,Neurosciences ,Multiple Sclerosis ,Brain Disorders ,Clinical Research ,2.1 Biological and endogenous factors ,Aetiology ,Neurological ,Inflammatory and immune system ,Infection ,Good Health and Well Being ,Adult ,B-Lymphocytes ,Central Nervous System ,Chemokines ,Cytokines ,Female ,Flow Cytometry ,Humans ,Immunoglobulin G ,Immunoglobulin Heavy Chains ,Inflammation ,Male ,Middle Aged ,Transcriptome ,multiple sclerosis ,neuroimmunology ,B cell ,immune repertoire ,University of California ,San Francisco MS-EPIC Team - Abstract
Central nervous system B cells have several potential roles in multiple sclerosis (MS): secretors of proinflammatory cytokines and chemokines, presenters of autoantigens to T cells, producers of pathogenic antibodies, and reservoirs for viruses that trigger demyelination. To interrogate these roles, single-cell RNA sequencing (scRNA-Seq) was performed on paired cerebrospinal fluid (CSF) and blood from subjects with relapsing-remitting MS (RRMS; n = 12), other neurologic diseases (ONDs; n = 1), and healthy controls (HCs; n = 3). Single-cell immunoglobulin sequencing (scIg-Seq) was performed on a subset of these subjects and additional RRMS (n = 4), clinically isolated syndrome (n = 2), and OND (n = 2) subjects. Further, paired CSF and blood B cell subsets (RRMS; n = 7) were isolated using fluorescence activated cell sorting for bulk RNA sequencing (RNA-Seq). Independent analyses across technologies demonstrated that nuclear factor kappa B (NF-κB) and cholesterol biosynthesis pathways were activated, and specific cytokine and chemokine receptors were up-regulated in CSF memory B cells. Further, SMAD/TGF-β1 signaling was down-regulated in CSF plasmablasts/plasma cells. Clonally expanded, somatically hypermutated IgM+ and IgG1+ CSF B cells were associated with inflammation, blood-brain barrier breakdown, and intrathecal Ig synthesis. While we identified memory B cells and plasmablast/plasma cells with highly similar Ig heavy-chain sequences across MS subjects, similarities were also identified with ONDs and HCs. No viral transcripts, including from Epstein-Barr virus, were detected. Our findings support the hypothesis that in MS, CSF B cells are driven to an inflammatory and clonally expanded memory and plasmablast/plasma cell phenotype.
- Published
- 2020
36. Ataxin-1 regulates B cell function and the severity of autoimmune experimental encephalomyelitis.
- Author
-
Didonna, Alessandro, Canto Puig, Ester, Ma, Qin, Matsunaga, Atsuko, Ho, Brenda, Caillier, Stacy J, Shams, Hengameh, Lee, Nicholas, Hauser, Stephen L, Tan, Qiumin, Zamvil, Scott S, and Oksenberg, Jorge R
- Subjects
B-Lymphocytes ,Animals ,Mice ,Knockout ,Mice ,Multiple Sclerosis ,Encephalomyelitis ,Autoimmune ,Experimental ,Signal Transduction ,Cell Proliferation ,Antigen Presentation ,Ataxin-1 ,B cells ,antigen presentation ,ataxin-1 ,autoimmunity ,multiple sclerosis ,Autoimmune Disease ,Brain Disorders ,Genetics ,Neurodegenerative ,Neurosciences ,2.1 Biological and endogenous factors ,1.1 Normal biological development and functioning ,Underpinning research ,Aetiology ,Neurological - Abstract
Ataxin-1 (ATXN1) is a ubiquitous polyglutamine protein expressed primarily in the nucleus where it binds chromatin and functions as a transcriptional repressor. Mutant forms of ataxin-1 containing expanded glutamine stretches cause the movement disorder spinocerebellar ataxia type 1 (SCA1) through a toxic gain-of-function mechanism in the cerebellum. Conversely, ATXN1 loss-of-function is implicated in cancer development and Alzheimer's disease (AD) pathogenesis. ATXN1 was recently nominated as a susceptibility locus for multiple sclerosis (MS). Here, we show that Atxn1-null mice develop a more severe experimental autoimmune encephalomyelitis (EAE) course compared to wildtype mice. The aggravated phenotype is mediated by increased T helper type 1 (Th1) cell polarization, which in turn results from the dysregulation of B cell activity. Ataxin-1 ablation in B cells leads to aberrant expression of key costimulatory molecules involved in proinflammatory T cell differentiation, including cluster of differentiation (CD)44 and CD80. In addition, comprehensive phosphoflow cytometry and transcriptional profiling link the exaggerated proliferation of ataxin-1 deficient B cells to the activation of extracellular signal-regulated kinase (ERK) and signal transducer and activator of transcription (STAT) pathways. Lastly, selective deletion of the physiological binding partner capicua (CIC) demonstrates the importance of ATXN1 native interactions for correct B cell functioning. Altogether, we report a immunomodulatory role for ataxin-1 and provide a functional description of the ATXN1 locus genetic association with MS risk.
- Published
- 2020
37. High-resolution epitope mapping of anti-Hu and anti-Yo autoimmunity by programmable phage display
- Author
-
O’Donovan, Brian, Mandel-Brehm, Caleigh, Vazquez, Sara E, Liu, Jamin, Parent, Audrey V, Anderson, Mark S, Kassimatis, Travis, Zekeridou, Anastasia, Hauser, Stephen L, Pittock, Sean J, Chow, Eric, Wilson, Michael R, and DeRisi, Joseph L
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Genetics ,Neurosciences ,Biotechnology ,2.1 Biological and endogenous factors ,Aetiology ,phage display ,autoimmunity ,anti-Hu ,anti-Yo ,paraneoplastic ,Clinical sciences ,Biological psychology - Abstract
Paraneoplastic neurological disorders are immune-mediated diseases understood to manifest as part of a misdirected anti-tumor immune response. Paraneoplastic neurological disorder-associated autoantibodies can assist with diagnosis and enhance our understanding of tumor-associated immune processes. We designed a comprehensive library of 49-amino-acid overlapping peptides spanning the entire human proteome, including all splicing isoforms and computationally predicted coding regions. Using this library, we optimized a phage immunoprecipitation and sequencing protocol with multiple rounds of enrichment to create high-resolution epitope profiles in serum and cerebrospinal fluid (CSF) samples from patients suffering from two common paraneoplastic neurological disorders, the anti-Yo (n = 36 patients) and anti-Hu (n = 44 patients) syndromes. All (100%) anti-Yo patient samples yielded enrichment of peptides from the canonical anti-Yo (CDR2 and CDR2L) antigens, while 38% of anti-Hu patients enriched peptides deriving from the nELAVL (neuronal embryonic lethal abnormal vision like) family of proteins, the anti-Hu autoantigenic target. Among the anti-Hu patient samples that were positive for nELAVL, we noted a restricted region of immunoreactivity. To achieve single amino acid resolution, we designed a novel deep mutational scanning phage library encoding all possible single-point mutants targeting the reactive nELAVL region. This analysis revealed a distinct preference for the degenerate motif, RLDxLL, shared by ELAVL2, 3 and 4. Lastly, phage immunoprecipitation sequencing identified several known autoantigens in these same patient samples, including peptides deriving from the cancer-associated antigens ZIC and SOX families of transcription factors. Overall, this optimized phage immunoprecipitation sequencing library and protocol yielded the high-resolution epitope mapping of the autoantigens targeted in anti-Yo and anti-Hu encephalitis patients to date. The results presented here further demonstrate the utility and high-resolution capability of phage immunoprecipitation sequencing for both basic science and clinical applications and for better understanding the antigenic targets and triggers of paraneoplastic neurological disorders.
- Published
- 2020
38. Serum antibodies to phosphatidylcholine in MS.
- Author
-
Sádaba, Maria Cruz, Rothhammer, Veit, Muñoz, Úrsula, Sebal, Cristina, Escudero, Esther, Kivisäkk, Pia, Garcia Sanchez, Maria Isabel, Izquierdo, Guillermo, Hauser, Stephen L, Baranzini, Sergio E, Oksenberg, Jorge R, Álvarez-Lafuente, Roberto, Bakshi, Rohit, Weiner, Howard L, and Quintana, Francisco J
- Subjects
Humans ,Multiple Sclerosis ,Lactosylceramides ,Phosphatidylcholines ,Immunoglobulin G ,Immunoglobulin M ,Autoantibodies ,Cohort Studies ,Adult ,Aged ,Aged ,80 and over ,Middle Aged ,Female ,Male ,Young Adult ,Biomarkers ,Brain Disorders ,Prevention ,Autoimmune Disease ,Neurodegenerative ,Neurosciences - Abstract
To evaluate the value of serum immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies reactive with phosphatidylcholine (PC) and lactosylceramide (LC) as biomarkers in MS. We developed an ultrasensitive ELISA technique to analyze serum IgG and IgM antibodies to LC and PC, which we used to analyze samples from 362 patients with MS, 10 patients with non-MS myelin diseases (Non-MSMYDs), 11 patients with nonmyelin neurologic diseases (Non-MYNDs), and 80 controls. MS serum samples included clinically isolated syndrome (CIS, n = 17), relapsing-remitting MS (RRMS, n = 62), secondary progressive MS (SPMS, n = 50), primary progressive MS (PPMS, n = 37), and benign MS (BENMS, n = 36). We detected higher levels of serum IgM antibodies to PC (IgM-PC) in MS than control samples; patients with CIS and RRMS showed higher IgM-PC levels than patients with SPMS, PPMS, and BENMS and controls. MS and control samples did not differ in serum levels of IgM antibodies reactive with LC, nor in IgG antibodies reactive with LC or PC. Serum IgM-PC antibodies are elevated in patients with MS, particularly during the CIS and RRMS phases of the disease. Thus, serum IgM-PC is a candidate biomarker for early inflammatory stages of MS. This study provides Class III evidence that serum antibodies to PC are elevated in patients with MS. The study is rated Class III because of the case control design and the risk of spectrum bias: antibody levels in patients with MS were compared with healthy controls.
- Published
- 2020
39. Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study
- Author
-
Bakshi, Rohit, Healy, Brian C, Dupuy, Sheena L, Kirkish, Gina, Khalid, Fariha, Gundel, Tristan, Asteggiano, Carlo, Yousuf, Fawad, Alexander, Amber, Hauser, Stephen L, Weiner, Howard L, Henry, Roland G, and consortium, SUMMIT
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Brain Disorders ,Autoimmune Disease ,Multiple Sclerosis ,Neurodegenerative ,Clinical Research ,Biomedical Imaging ,Neurosciences ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Neurological ,Adult ,Atrophy ,Brain ,Cohort Studies ,Disease Progression ,Female ,Humans ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Prognosis ,Young Adult ,Multiple sclerosis ,MRI ,brain ,neuroimaging ,disability ,multicenter study ,SUMMIT consortium ,Neurology & Neurosurgery ,Clinical sciences ,Biological psychology - Abstract
Background and purposeBrain MRI-derived lesions and atrophy are related to multiple sclerosis (MS) disability. In the Serially Unified Multicenter MS Investigation (SUMMIT), from Brigham and Women's Hospital (BWH) and University of California, San Francisco (UCSF), we assessed whether MRI methodologic heterogeneity may limit the ability to pool multisite data sets to assess 5-year clinical-MRI associations.MethodsPatients with relapsing-remitting (RR) MS (n = 100 from each site) underwent baseline brain MRI and baseline and 5-year clinical evaluations. Patients were matched on sex (74 women each), age, disease duration, and Expanded Disability Status Scale (EDSS) score. MRI was performed with differences between sites in both acquisition (field strength, voxel size, pulse sequences), and postprocessing pipeline to assess brain parenchymal fraction (BPF) and T2 lesion volume (T2LV).ResultsThe UCSF cohort showed higher correlation than the BWH cohort between T2LV and disease duration. UCSF showed a higher inverse correlation between BPF and age than BWH. UCSF showed a higher inverse correlation than BWH between BPF and 5-year EDSS score. Both cohorts showed inverse correlations between BPF and T2LV, with no between-site difference. The pooled but not individual cohort data showed a link between a lower baseline BPF and the subsequent 5-year worsening in disability in addition to other stronger relationships in the data.ConclusionsMRI acquisition and processing differences may result in some degree of heterogeneity in assessing brain lesion and atrophy measures in patients with MS. Pooling of data across sites is beneficial to correct for potential biases in individual data sets.
- Published
- 2020
40. Intersubject Variability and Normalization Strategies for Spinal Cord Total Cross‐Sectional and Gray Matter Areas
- Author
-
Papinutto, Nico, Asteggiano, Carlo, Bischof, Antje, Gundel, Tristan J, Caverzasi, Eduardo, Stern, William A, Bastianello, Stefano, Hauser, Stephen L, and Henry, Roland G
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Neurosciences ,Spinal Cord Injury ,Prevention ,Physical Injury - Accidents and Adverse Effects ,Traumatic Head and Spine Injury ,Neurodegenerative ,Biomedical Imaging ,Clinical Research ,Neurological ,Adult ,Aged ,Female ,Gray Matter ,Healthy Volunteers ,Humans ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Organ Size ,Sex Characteristics ,Spinal Cord ,White Matter ,Young Adult ,Intersubject variability ,magnetic resonance imaging ,morphometry ,normalization strategies ,spinal cord ,Neurology & Neurosurgery ,Clinical sciences ,Biological psychology - Abstract
Background and purposeThe quantification of spinal cord (SC) atrophy by MRI has assumed an important role in assessment of neuroinflammatory/neurodegenerative diseases and traumatic SC injury. Recent technical advances make possible the quantification of gray matter (GM) and white matter tissues in clinical settings. However, the goal of a reliable diagnostic, prognostic or predictive marker is still elusive, in part due to large intersubject variability of SC areas. Here, we investigated the sources of this variability and explored effective strategies to reduce it.MethodsOne hundred twenty-nine healthy subjects (mean age: 41.0 ± 15.9) underwent MRI on a Siemens 3T Skyra scanner. Two-dimensional PSIR at the C2-C3 vertebral level and a sagittal 1 mm3 3D T1-weighted brain acquisition extended to the upper cervical cord were acquired. Total cross-sectional area and GM area were measured at C2-C3, as well as measures of the vertebra, spinal canal and the skull. Correlations between the different metrics were explored using Pearson product-moment coefficients. The most promising metrics were used to normalize cord areas using multiple regression analyses.ResultsThe most effective normalization metrics were the V-scale (from SienaX) and the product of the C2-C3 spinal canal diameters. Normalization methods based on these metrics reduced the intersubject variability of cord areas of up to 17.74%. The measured cord areas had a statistically significant sex difference, while the effect of age was moderate.ConclusionsThe present work explored in a large cohort of healthy subjects the source of intersubject variability of SC areas and proposes effective normalization methods for its reduction.
- Published
- 2020
41. Imaging correlates of visual function in multiple sclerosis.
- Author
-
Caverzasi, Eduardo, Cordano, Christian, Zhu, Alyssa H, Zhao, Chao, Bischof, Antje, Kirkish, Gina, Bennett, Daniel J, Devereux, Michael, Baker, Nicholas, Inman, Justin, Yiu, Hao H, Papinutto, Nico, Gelfand, Jeffrey M, Cree, Bruce AC, Hauser, Stephen L, Henry, Roland G, and Green, Ari J
- Subjects
Brain ,Myelin Sheath ,Retina ,Humans ,Multiple Sclerosis ,Magnetic Resonance Imaging ,Tomography ,Optical Coherence ,Adult ,Middle Aged ,Female ,Male ,Vision ,Ocular ,Brain Disorders ,Eye Disease and Disorders of Vision ,Neurosciences ,Clinical Research ,Neurodegenerative ,Biomedical Imaging ,Autoimmune Disease ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Eye ,Neurological ,General Science & Technology - Abstract
No single neuroimaging technique or sequence is capable of reflecting the functional deficits manifest in MS. Given the interest in imaging biomarkers for short- to medium-term studies, we aimed to assess which imaging metrics might best represent functional impairment for monitoring in clinical trials. Given the complexity of functional impairment in MS, however, it is useful to isolate a particular functionally relevant pathway to understand the relationship between imaging and neurological function. We therefore analyzed existing data, combining multiparametric MRI and OCT to describe MS associated visual impairment. We assessed baseline data from fifty MS patients enrolled in ReBUILD, a prospective trial assessing the effect of a remyelinating drug (clemastine). Subjects underwent 3T MRI imaging, including Neurite Orientation Dispersion and Density Imaging (NODDI), myelin content quantification, and retinal imaging, using OCT. Visual function was assessed, using low-contrast letter acuity. MRI and OCT data were studied to model visual function in MS, using a partial, least-squares, regression analysis. Measures of neurodegeneration along the entire visual pathway, described most of the observed variance in visual disability, measured by low contrast letter acuity. In those patients with an identified history of ON, however, putative myelin measures also showed correlation with visual performance. In the absence of clinically identifiable inflammatory episodes, residual disability correlates with neurodegeneration, whereas after an identifiable exacerbation, putative measures of myelin content are additionally informative.
- Published
- 2020
42. Anti-CD20 therapy depletes activated myelin-specific CD8+ T cells in multiple sclerosis
- Author
-
Sabatino, Joseph J, Wilson, Michael R, Calabresi, Peter A, Hauser, Stephen L, Schneck, Jonathan P, and Zamvil, Scott S
- Subjects
Brain Disorders ,Clinical Research ,Influenza ,Multiple Sclerosis ,Autoimmune Disease ,Neurodegenerative ,Prevention ,Neurosciences ,Aetiology ,2.1 Biological and endogenous factors ,Neurological ,Adolescent ,Adult ,Antibodies ,Monoclonal ,Antigens ,CD20 ,CD8-Positive T-Lymphocytes ,Cells ,Cultured ,Female ,Humans ,Male ,Middle Aged ,Myelin Proteins ,Young Adult ,multiple sclerosis ,CD8(+) T cells ,myelin antigen ,anti-CD20 therapy ,CD8+ T cells - Abstract
CD8+ T cells are believed to play an important role in multiple sclerosis (MS), yet their role in MS pathogenesis remains poorly defined. Although myelin proteins are considered potential autoantigenic targets, prior studies of myelin-reactive CD8+ T cells in MS have relied on in vitro stimulation, thereby limiting accurate measurement of their ex vivo precursor frequencies and phenotypes. Peptide:MHC I tetramers were used to identify and validate 5 myelin CD8+ T cell epitopes, including 2 newly described determinants in humans. The validated tetramers were used to measure the ex vivo precursor frequencies and phenotypes of myelin-specific CD8+ T cells in the peripheral blood of untreated MS patients and HLA allele-matched healthy controls. In parallel, CD8+ T cell responses against immunodominant influenza epitopes were also measured. There were no differences in ex vivo frequencies of tetramer-positive myelin-specific CD8+ T cells between MS patients and control subjects. An increased proportion of myelin-specific CD8+ T cells in MS patients exhibited a memory phenotype and expressed CD20 compared to control subjects, while there were no phenotypic differences observed among influenza-specific CD8+ T cells. Longitudinal assessments were also measured in a subset of MS patients subsequently treated with anti-CD20 monoclonal antibody therapy. The proportion of memory and CD20+ CD8+ T cells specific for certain myelin but not influenza epitopes was significantly reduced following anti-CD20 treatment. This study, representing a characterization of unmanipulated myelin-reactive CD8+ T cells in MS, indicates these cells may be attractive targets in MS therapy.
- Published
- 2019
43. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions
- Author
-
Elliott, Colm, Wolinsky, Jerry S, Hauser, Stephen L, Kappos, Ludwig, Barkhof, Frederik, Bernasconi, Corrado, Wei, Wei, Belachew, Shibeshih, and Arnold, Douglas L
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Biomedical Imaging ,Multiple Sclerosis ,Neurodegenerative ,Brain Disorders ,Clinical Research ,Autoimmune Disease ,Neurosciences ,Detection ,screening and diagnosis ,2.1 Biological and endogenous factors ,Aetiology ,4.2 Evaluation of markers and technologies ,Neurological ,Adult ,Brain ,Contrast Media ,Disease Progression ,Female ,Gadolinium ,Humans ,Longitudinal Studies ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Multiple Sclerosis ,Chronic Progressive ,Multiple Sclerosis ,Relapsing-Remitting ,White Matter ,Chronic active lesions ,progressive multiple sclerosis ,relapsing multiple sclerosis ,slowly expanding/evolving lesions ,smoldering plaques ,Neurology & Neurosurgery ,Clinical sciences ,Biological psychology - Abstract
BACKGROUND:Chronic lesion activity driven by smoldering inflammation is a pathological hallmark of progressive forms of multiple sclerosis (MS). OBJECTIVE:To develop a method for automatic detection of slowly expanding/evolving lesions (SELs) on conventional brain magnetic resonance imaging (MRI) and characterize such SELs in primary progressive MS (PPMS) and relapsing MS (RMS) populations. METHODS:We defined SELs as contiguous regions of existing T2 lesions showing local expansion assessed by the Jacobian determinant of the deformation between reference and follow-up scans. SEL candidates were assigned a heuristic score based on concentricity and constancy of change in T2- and T1-weighted MRIs. SELs were examined in 1334 RMS patients and 555 PPMS patients. RESULTS:Compared with RMS patients, PPMS patients had higher numbers of SELs (p = 0.002) and higher T2 volumes of SELs (p
- Published
- 2019
44. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
- Author
-
Barkhof, Frederik, Kappos, Ludwig, Wolinsky, Jerry S, Li, David KB, Bar-Or, Amit, Hartung, Hans-Peter, Belachew, Shibeshih, Han, Jian, Julian, Laura, Sauter, Annette, Napieralski, Julie, Koendgen, Harold, and Hauser, Stephen L
- Subjects
Clinical Trials and Supportive Activities ,Neurosciences ,Rare Diseases ,Multiple Sclerosis ,Clinical Research ,Brain Disorders ,Neurodegenerative ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Cancer ,Adjuvants ,Immunologic ,Adult ,Antibodies ,Monoclonal ,Humanized ,Brain ,Female ,Humans ,Immunologic Factors ,Interferon beta-1a ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Multiple Sclerosis ,Relapsing-Remitting ,Recurrence ,Time Factors ,Treatment Outcome ,Clinical Sciences ,Cognitive Sciences ,Neurology & Neurosurgery - Abstract
OBJECTIVE:To assess the onset of ocrelizumab efficacy on brain MRI measures of disease activity in the phase II study in relapsing-remitting multiple sclerosis (RRMS), and relapse rate in the pooled phase III studies in relapsing multiple sclerosis (RMS). METHODS:Brain MRI activity was determined in the phase II trial at monthly intervals in patients with RRMS receiving placebo, ocrelizumab (600 mg), or intramuscular interferon (IFN) β-1a (30 μg). Annualized relapse rate (ARR; over various epochs) and time to first relapse were analyzed in the pooled population of the phase III OPERA (A Study of Ocrelizumab in Comparison With Interferon Beta-1a [Rebif] in Participants With Relapsing Multiple Sclerosis) I and OPERA II trials in patients with RMS receiving ocrelizumab (600 mg) or subcutaneous IFN-β-1a (44 μg). RESULTS:In patients with RRMS, ocrelizumab reduced the number of new T1 gadolinium-enhancing lesions by week 4 vs placebo (p = 0.042) and by week 8 vs intramuscular IFN-β-1a (p < 0.001). Ocrelizumab also reduced the number of new or enlarging T2 lesions appearing between weeks 4 and 8 vs both placebo and IFN-β-1a (both p < 0.001). In patients with RMS, ocrelizumab significantly reduced ARR (p = 0.005) and the probability of time to first protocol-defined relapse (p = 0.014) vs subcutaneous IFN-β-1a within the first 8 weeks. CONCLUSION:Epoch analysis of MRI-measured lesion activity in the phase II study and relapse rate in the phase III studies consistently revealed a rapid suppression of acute MRI and clinical disease activity following treatment initiation with ocrelizumab in patients with RRMS and RMS, respectively. CLASSIFICATION OF EVIDENCE:This study provides Class II evidence that for patients with RRMS and RMS, ocrelizumab suppressed MRI activity within 4 weeks and clinical disease activity within 8 weeks.
- Published
- 2019
45. Telomere Length Is Associated with Disability Progression in Multiple Sclerosis.
- Author
-
Krysko, Kristen M, Henry, Roland G, Cree, Bruce AC, Lin, Jue, University of California, San Francisco MS-EPIC Team, Caillier, Stacy, Santaniello, Adam, Zhao, Chao, Gomez, Refujia, Bevan, Carolyn, Smith, Dana L, Stern, William, Kirkish, Gina, Hauser, Stephen L, Oksenberg, Jorge R, and Graves, Jennifer S
- Subjects
University of California ,San Francisco MS-EPIC Team ,Telomere ,Humans ,Multiple Sclerosis ,Disease Progression ,Disability Evaluation ,Cohort Studies ,Cross-Sectional Studies ,Aging ,Adult ,Middle Aged ,Female ,Male ,Telomere Homeostasis ,Cellular Senescence ,Clinical Research ,Neurodegenerative ,Brain Disorders ,Neurosciences ,Genetics ,Neurological ,Clinical Sciences ,Neurology & Neurosurgery - Abstract
OBJECTIVE:To assess whether biological aging as measured by leukocyte telomere length (LTL) is associated with clinical disability and brain volume loss in multiple sclerosis (MS). METHODS:Adults with MS/clinically isolated syndrome in the University of California, San Francisco EPIC cohort study were included. LTL was measured on DNA samples by quantitative polymerase chain reaction and expressed as telomere to somatic DNA (T/S) ratio. Expanded Disability Status Scale (EDSS) and 3-dimensional T1-weighted brain magnetic resonance imaging were performed at baseline and follow-up. Associations of baseline LTL with cross-sectional and longitudinal outcomes were assessed using simple and mixed effects linear regression models. A subset (n = 46) had LTL measured over time, and we assessed the association of LTL change with EDSS change with mixed effects models. RESULTS:Included were 356 women and 160 men (mean age = 43 years, median disease duration = 6 years, median EDSS = 1.5 [range = 0-7], mean T/S ratio = 0.97 [standard deviation = 0.18]). In baseline analyses adjusted for age, disease duration, and sex, for every 0.2 lower LTL, EDSS was 0.27 higher (95% confidence interval [CI] = 0.13-0.42, p
- Published
- 2019
46. Contribution of normal aging to brain atrophy in MS
- Author
-
Azevedo, Christina J, Cen, Steven Y, Jaberzadeh, Amir, Zheng, Ling, Hauser, Stephen L, and Pelletier, Daniel
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Brain Disorders ,Biomedical Imaging ,Aging ,Neurosciences ,Neurological ,Adult ,Aged ,Atrophy ,Brain Diseases ,Caudate Nucleus ,Female ,Gray Matter ,Humans ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Multiple Sclerosis ,Relapsing-Remitting ,Prospective Studies ,Putamen ,Thalamus - Abstract
To identify the top brain regions affected by MS-specific atrophy (i.e., atrophy in excess of normal aging) and to test whether normal aging and MS-specific atrophy increase or decrease in these regions with age. Six hundred fifty subjects (2,790 MRI time points) were analyzed: 520 subjects with relapse-onset MS from a 5-year prospective cohort with annual standardized 1-mm 3D T1-weighted images (3DT1s; 2,483 MRIs) and 130 healthy controls with longitudinal 3DT1s (307 MRIs). Rates of change in all FreeSurfer regions (v5.3) and Structural Image Evaluation Using Normalization of Atrophy (SIENA) were estimated with mixed-effects models. All FreeSurfer regions were ranked by the MS-specific atrophy slope/standard error ratio (βMS × time/SEβMS × time). In the top regions, age was added as an effect modifier to test whether MS-specific atrophy varied by age. The top-ranked regions were all gray matter structures. For SIENA, normal aging increased from 0.01%/y at age 30 years to -0.31%/y at age 60 years (-0.11% ± 0.032%/decade, p < 0.01), whereas MS-specific atrophy decreased from -0.38%/y at age 30 years to -0.12%/y at age 60 years (0.09% ± 0.035%/decade, p = 0.01). Similarly, in the thalamus, normal aging increased from -0.15%/y at age 30 years to -0.62%/y at age 60 years (-0.16% ± 0.079%/decade, p < 0.05), and MS-specific atrophy decreased from -0.59%/y at age 30 years to -0.05%/y at age 60 years (0.18% ± 0.08%/decade, p < 0.05). In the putamen and caudate, normal aging and MS-specific atrophy did not vary by age. For SIENA and thalamic atrophy, the contribution of normal aging increases with age, but does not change in the putamen and caudate. This may have substantial implications to understand the biology of brain atrophy in MS.
- Published
- 2019
47. Pan-viral serology implicates enteroviruses in acute flaccid myelitis
- Author
-
Schubert, Ryan D, Hawes, Isobel A, Ramachandran, Prashanth S, Ramesh, Akshaya, Crawford, Emily D, Pak, John E, Wu, Wesley, Cheung, Carly K, O’Donovan, Brian D, Tato, Cristina M, Lyden, Amy, Tan, Michelle, Sit, Rene, Sowa, Gavin M, Sample, Hannah A, Zorn, Kelsey C, Banerji, Debarko, Khan, Lillian M, Bove, Riley, Hauser, Stephen L, Gelfand, Amy A, Johnson-Kerner, Bethany L, Nash, Kendall, Krishnamoorthy, Kalpathy S, Chitnis, Tanuja, Ding, Joy Z, McMillan, Hugh J, Chiu, Charles Y, Briggs, Benjamin, Glaser, Carol A, Yen, Cynthia, Chu, Victoria, Wadford, Debra A, Dominguez, Samuel R, Ng, Terry Fei Fan, Marine, Rachel L, Lopez, Adriana S, Nix, W Allan, Soldatos, Ariane, Gorman, Mark P, Benson, Leslie, Messacar, Kevin, Konopka-Anstadt, Jennifer L, Oberste, M Steven, DeRisi, Joseph L, and Wilson, Michael R
- Subjects
Biomedical and Clinical Sciences ,Health Sciences ,Neurosciences ,Biotechnology ,Rare Diseases ,Pediatric ,2.1 Biological and endogenous factors ,Good Health and Well Being ,Antibodies ,Viral ,Antigens ,Viral ,Central Nervous System Viral Diseases ,Child ,Preschool ,Enterovirus ,Enterovirus Infections ,Female ,Humans ,Infant ,Male ,Myelitis ,Neuromuscular Diseases ,Seroepidemiologic Studies ,United States ,Medical and Health Sciences ,Immunology ,Biomedical and clinical sciences ,Health sciences - Abstract
Since 2012, the United States of America has experienced a biennial spike in pediatric acute flaccid myelitis (AFM)1-6. Epidemiologic evidence suggests non-polio enteroviruses (EVs) are a potential etiology, yet EV RNA is rarely detected in cerebrospinal fluid (CSF)2. CSF from children with AFM (n = 42) and other pediatric neurologic disease controls (n = 58) were investigated for intrathecal antiviral antibodies, using a phage display library expressing 481,966 overlapping peptides derived from all known vertebrate and arboviruses (VirScan). Metagenomic next-generation sequencing (mNGS) of AFM CSF RNA (n = 20 cases) was also performed, both unbiased sequencing and with targeted enrichment for EVs. Using VirScan, the viral family significantly enriched by the CSF of AFM cases relative to controls was Picornaviridae, with the most enriched Picornaviridae peptides belonging to the genus Enterovirus (n = 29/42 cases versus 4/58 controls). EV VP1 ELISA confirmed this finding (n = 22/26 cases versus 7/50 controls). mNGS did not detect additional EV RNA. Despite rare detection of EV RNA, pan-viral serology frequently identified high levels of CSF EV-specific antibodies in AFM compared with controls, providing further evidence for a causal role of non-polio EVs in AFM.
- Published
- 2019
48. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis
- Author
-
Elliott, Colm, Belachew, Shibeshih, Wolinsky, Jerry S, Hauser, Stephen L, Kappos, Ludwig, Barkhof, Frederik, Bernasconi, Corrado, Fecker, Julian, Model, Fabian, Wei, Wei, and Arnold, Douglas L
- Subjects
Clinical Research ,Biomedical Imaging ,Neurosciences ,Clinical Trials and Supportive Activities ,Neurodegenerative ,Autoimmune Disease ,Multiple Sclerosis ,Brain Disorders ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Neurological ,Adult ,Antibodies ,Monoclonal ,Humanized ,Disease Progression ,Double-Blind Method ,Female ,Humans ,Immunologic Factors ,Longitudinal Studies ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Multiple Sclerosis ,Chronic Progressive ,Predictive Value of Tests ,White Matter ,MS: imaging ,MS: biomarkers ,MS: clinical trials ,neuroinflammation ,white matter lesion ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Neurology & Neurosurgery - Abstract
Chronic active and slowly expanding lesions with smouldering inflammation are neuropathological correlates of progressive multiple sclerosis pathology. T1 hypointense volume and signal intensity on T1-weighted MRI reflect brain tissue damage that may develop within newly formed acute focal inflammatory lesions or in chronic pre-existing lesions without signs of acute inflammation. Using a recently developed method to identify slowly expanding/evolving lesions in vivo from longitudinal conventional T2- and T1-weighted brain MRI scans, we measured the relative amount of chronic lesion activity as measured by change in T1 volume and intensity within slowly expanding/evolving lesions and non-slowly expanding/evolving lesion areas of baseline pre-existing T2 lesions, and assessed the effect of ocrelizumab on this outcome in patients with primary progressive multiple sclerosis participating in the phase III, randomized, placebo-controlled, double-blind ORATORIO study (n = 732, NCT01194570). We also assessed the predictive value of T1-weighted measures of chronic lesion activity for clinical multiple sclerosis progression as reflected by a composite disability measure including the Expanded Disability Status Scale, Timed 25-Foot Walk and 9-Hole Peg Test. We observed in this clinical trial population that most of total brain non-enhancing T1 hypointense lesion volume accumulation was derived from chronic lesion activity within pre-existing T2 lesions rather than new T2 lesion formation. There was a larger decrease in mean normalized T1 signal intensity and greater relative accumulation of T1 hypointense volume in slowly expanding/evolving lesions compared with non-slowly expanding/evolving lesions. Chronic white matter lesion activity measured by longitudinal T1 hypointense lesion volume accumulation in slowly expanding/evolving lesions and in non-slowly expanding/evolving lesion areas of pre-existing lesions predicted subsequent composite disability progression with consistent trends on all components of the composite. In contrast, whole brain volume loss and acute lesion activity measured by longitudinal T1 hypointense lesion volume accumulation in new focal T2 lesions did not predict subsequent composite disability progression in this trial at the population level. Ocrelizumab reduced longitudinal measures of chronic lesion activity such as T1 hypointense lesion volume accumulation and mean normalized T1 signal intensity decrease both within regions of pre-existing T2 lesions identified as slowly expanding/evolving and in non-slowly expanding/evolving lesions. Using conventional brain MRI, T1-weighted intensity-based measures of chronic white matter lesion activity predict clinical progression in primary progressive multiple sclerosis and may qualify as a longitudinal in vivo neuroimaging correlate of smouldering demyelination and axonal loss in chronic active lesions due to CNS-resident inflammation and/or secondary neurodegeneration across the multiple sclerosis disease continuum.
- Published
- 2019
49. Reply to “Silent Progression or Bout Onset Progressive Multiple Sclerosis?”
- Author
-
Cree, Bruce AC and Hauser, Stephen L
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Clinical Sciences ,Disease Progression ,Humans ,Multiple Sclerosis ,Multiple Sclerosis ,Chronic Progressive ,Recurrence ,Neurology & Neurosurgery ,Clinical sciences - Published
- 2019
50. Opposing T cell responses in experimental autoimmune encephalomyelitis
- Author
-
Saligrama, Naresha, Zhao, Fan, Sikora, Michael J, Serratelli, William S, Fernandes, Ricardo A, Louis, David M, Yao, Winnie, Ji, Xuhuai, Idoyaga, Juliana, Mahajan, Vinit B, Steinmetz, Lars M, Chien, Yueh-Hsiu, Hauser, Stephen L, Oksenberg, Jorge R, Garcia, K Christopher, and Davis, Mark M
- Subjects
Neurosciences ,Autoimmune Disease ,Neurodegenerative ,Multiple Sclerosis ,Brain Disorders ,2.1 Biological and endogenous factors ,Aetiology ,Neurological ,Inflammatory and immune system ,Adult ,Animals ,CD4-Positive T-Lymphocytes ,CD8-Positive T-Lymphocytes ,Celiac Disease ,Clone Cells ,Encephalomyelitis ,Autoimmune ,Experimental ,Female ,H-2 Antigens ,Humans ,Immunization ,Lymphocyte Activation ,Male ,Mice ,Mice ,Inbred C57BL ,Middle Aged ,Myelin-Associated Glycoprotein ,Receptors ,Antigen ,T-Cell ,T-Lymphocytes ,T-Lymphocytes ,Regulatory ,Young Adult ,General Science & Technology - Abstract
Experimental autoimmune encephalomyelitis is a model for multiple sclerosis. Here we show that induction generates successive waves of clonally expanded CD4+, CD8+ and γδ+ T cells in the blood and central nervous system, similar to gluten-challenge studies of patients with coeliac disease. We also find major expansions of CD8+ T cells in patients with multiple sclerosis. In autoimmune encephalomyelitis, we find that most expanded CD4+ T cells are specific for the inducing myelin peptide MOG35-55. By contrast, surrogate peptides derived from a yeast peptide major histocompatibility complex library of some of the clonally expanded CD8+ T cells inhibit disease by suppressing the proliferation of MOG-specific CD4+ T cells. These results suggest that the induction of autoreactive CD4+ T cells triggers an opposing mobilization of regulatory CD8+ T cells.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.